## CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>President’s Welcome</td>
<td>3</td>
</tr>
<tr>
<td>Committees &amp; Chairs</td>
<td>4</td>
</tr>
<tr>
<td>General Information</td>
<td>5-6</td>
</tr>
<tr>
<td>Overseas Invited Speakers</td>
<td>9-11</td>
</tr>
<tr>
<td>Social Events</td>
<td>12</td>
</tr>
<tr>
<td>Plenary Sessions</td>
<td>13</td>
</tr>
<tr>
<td>At a Glance Programme</td>
<td>14-17</td>
</tr>
<tr>
<td><strong>Boot Camp</strong></td>
<td>14</td>
</tr>
<tr>
<td><strong>Monday</strong></td>
<td>15</td>
</tr>
<tr>
<td><strong>Tuesday</strong></td>
<td>16</td>
</tr>
<tr>
<td><strong>Wednesday</strong></td>
<td>17</td>
</tr>
<tr>
<td><strong>Full Programme</strong></td>
<td>18-30</td>
</tr>
<tr>
<td><strong>Boot Camp</strong></td>
<td>18-19</td>
</tr>
<tr>
<td><strong>Monday</strong></td>
<td>20-24</td>
</tr>
<tr>
<td><strong>Tuesday</strong></td>
<td>25-28</td>
</tr>
<tr>
<td><strong>Wednesday</strong></td>
<td>29-30</td>
</tr>
<tr>
<td>Posters</td>
<td>31-37</td>
</tr>
<tr>
<td>Exhibition Floor Plan</td>
<td>38</td>
</tr>
<tr>
<td>2015 Exhibitor Profiles A-Z</td>
<td>39-41</td>
</tr>
<tr>
<td>Venue Plan</td>
<td>42</td>
</tr>
<tr>
<td>Brighton Map</td>
<td>43</td>
</tr>
</tbody>
</table>
Welcome to BNMS annual meeting 2015

On behalf of the British Nuclear Medicine Society, it is a pleasure to welcome you to the 43rd annual spring meeting in Brighton. The meeting will kick off with the ever popular Boot Camp Programme which now has parallel clinicians' and practitioner's sessions. The main meeting this year has a very diverse programme which addresses a wide variety of topics ranging from cutting edge advances in science and clinical practice to updates in routine investigations in daily practice with over 20 invited expert speakers and dozens of CPD lectures. I am particularly looking forward to the annual lecture delivered by Professor Macapinlac on the ‘Evolving role of clinical molecular imaging in multi-disciplinary cancer care.’ This year we also have an extensive number of daily focused “masterclasses”, on topics ranging from PET and therapy, to traditional nuclear medicine practices. In addition the meeting is a forum for presenting your own ongoing research and catching up with research from all over the world with over 200 abstract and poster presentations. You will also have a chance to identify and discuss the changing scene in training and regulatory aspects of nuclear medicine which affects us all.

This year is a special year, I am excited to announce the special event we are having to celebrating the 25th anniversary of the establishment of the BNMS Clinical Practitioners Group (formerly known as the Technologists Group), one of the first in the Europe. This is a great opportunity to meet past and present members of this group and remember and celebrate achievements of the past 25 years.

Do not miss the final day of the conference which will end traditionally with a lecture to give you an overview and highlights of the meeting, which I am delighted to say that Dr Brian Neilly has kindly agreed to undertake. The last day of the meeting is also the occasion when we celebrate the best, by awarding the prizes for best proffered presentations and posters delivered in the course of this three day event.

I would like to personally thank the tireless efforts of Prof Bomanji and Dr Gnanasegaran in orchestrating such an excellent and promising programme. I hope you will enjoy the meeting, taking away with you many memorable moments from the talks and lectures, the event itself and of course the beautiful seaside resort of Brighton.

To make it all easier for you we are launching our new app for mobile devices, which will enable you to navigate through the programme streamlining your selections and choices.

Finally I would like to remind you that plans are already in place for a very exciting BNMS annual spring meeting in Birmingham next year, when we shall be celebrating the 50th anniversary of the British Nuclear Medicine Society.

Dr Alp Notghi
BNMS President
### COMMITTEES & CHAIRS

#### SCIENTIFIC COMMITTEE
- Dr J Bomanji (Chair)
- Ms S Allen
- Dr P Arumugam
- Dr J Ballinger
- Dr T Barwick
- Dr A Bolster
- Mr A Bradley
- Mrs J Croasdale
- Dr B Drake
- Dr B Ellis
- Dr G Gnanasegaran
- Dr S Han
- Dr S Hughes
- Dr C Marshall
- Mr L Rowling
- Dr P Ryan (Poster Chair)
- Dr F Sundram

#### COUNCIL MEMBERS 2015/2016
- Dr A Notghi (President)
- Dr B Neilly (Past-President)
- Ms S Allen (Hon Secretary)
- Prof S Vinjamuri (Hon Treasurer)
- Dr G Flux
- Dr R Graham
- Ms C Greaves
- Ms J Croasdale
- Dr M Hall
- Dr K Wechalekar
- Mr Lloyd Rowling
- Dr D Neriman
- Dr A Corrigan
- Mr M Ward
- Ms C Lory
- Dr S Dizdarevic
- Mrs D Tolley
- Dr E Ellis
- Dr J Bomanji
- Dr G Gnanasegaran

#### CONFERENCE ORGANISATION
- Scientific Chair: Dr J Bomanji
- Education Chair: Dr G Gnanasegaran
- Poster Session Organiser: Dr P Ryan
- YIP judging: Dr F Sundram
- Prof S Vinjamuri
- Ms C Weston
- Ms N Fenning
- Mrs E Gilbert

#### POSTER JUDGES
- Sarah Allen
- Dr Partha Chaudary
- Dr Sabina Dizdarevic
- Dr Sai Han
- Andy Irwin
- Dr Vikram Lele
- Dr Nicola Mulholland
- Dr Khalid Nawaz
- Dr Emmanouil Panagiotidis
- Dr Nagabhushan Seshadri
- Chistopher Sibley-Allen
- Dr Shamuga Sundaram
- Dr Francis Sundram
- Dr Teresa Syzkho
- Dr Tagheer Toma
- Dr Kshama Wechalekar

#### CHAIRMEN
- Dr Rosemary Allan
- Sarah Allen
- Dr Parthiban Arumugam
- Samera Bangash
- Dr Lorenzo Giassoni
- Maria Burniston
- Dr Alexis Corrigan
- Jilly Croasdale
- Katherine Day
- Penny Delf
- Dr Sabina Dizdarevic
- Dr Brent Drake
- Dr Yong Du
- Dr Beverley Ellis
- Dr Gopinath Gnanasegaran
- Dr Richard Graham
- Dr Sai Han
- Paul Hinton
- Dr Simon Hughes
- Prof Drazen Huić
- Dr Brian Hutton
- Dr Jackie James
- Sandra Johns
- Dr Irfan Kayani
- Dr Vikram Lele
- Prof Jasna Mhailovic
- Dr N Mulholland
- Dr Nagesh Nagabhushan
- Dr Shaunak Navalkissoor
- Dr K Nawaz
- Dr Brian Neilly
- Dr Alp Notghi
- Prof Alan Perkins
- Dr Vineet Prakash
- Dr Robert Reid
- Lloyd Rowling
- Dr Paul Ryan
- Dr Andrew Scarsbrook
- Dr Francis Sundram
- Dr Rizwan Syed
- Dr Teresa Szyszko
- Dr Raghuveer Venkannagari
- Prof Sobhan Vinjamuri
- Dr Kshama Wechalekar
- Dr Wai-Lup Wong
Please note: CME/CPD certificates will be available for downloading from the BNMS website after the meeting, using your delegate ID number.

**COMMERCIAL EXHIBITION - 1st Floor**
Monday 09.00 – 19.30  
Tuesday 09.00 – 17.30

**CONFERENCE REGISTRATION**
On-line Registration only: www.bnms.org.uk  
After Wednesday 22nd April Tel: 0115 7484504 Email: office@bnms.org.uk

**EMERGENCY CONTACT NUMBER**
The emergency contact telephone number for delegates attending the conference is 01273 290 131

**FUTURE BNMS MEETINGS**
The BNMS Autumn Meeting 2015 will take place at the Royal Society of Medicine, London on Wednesday 2nd September.  
The BNMS Spring Meeting 2016 celebrating 50 years of the Society will take place at the ICC Birmingham on 17th – 19th April 2016.

**HOTEL ACCOMMODATION**
See hotel listing and booking form on the BNMS website http://www.bnms.org.uk/meetings-and-events/your-trip , Telephone 01273 292626 or email delegates@visitbrighton.com

**INTERNET ACCESS**
Free internet access is available for delegates in the Exhibition Hall on the BNMS stand no.26.

**DELEGATE BAGS**
Kindly sponsored by Bright Technologies

**LANYARDS**
Kindly sponsored by Philips

**PADS**
Kindly sponsored by Lilly UK

---

**APP**
This brochure is available as an APP to download. See the QR codes in the foyer and on the BNMS Stand

**AV ROOM**
The AV and Preview Room is located on the 1st Floor
Opening times:
- Sunday 12.00 – 18.00  
- Monday 08.00 – 18.30  
- Tuesday 08.00 – 18.30  
- Wednesday 08.00 – 12.00

**BADGES**
For organisational and security reasons, badges must be worn at the congress venue. Access to the conference areas will only be granted upon presentation of your badge.

**BNMS STAND & INTERNET ACCESS**
Computers with internet access are available on the BNMS Stand in the Exhibition Hall

**BOOK OF ABSTRACTS**
This is available in the latest edition of Nuclear medicine communications which can be found in the delegate bag. iPhone, iPad and Android users can view an electronic version of NMC May 2015 Edition which contains the abstract. Scan the QR code in the programme or follow the link in the app for a new way to experience the conference

**CATERING**
Cafe East situated on 1st floor will be open for the duration of the meeting selling hot and cold beverages, confectionery, snacks and sandwiches”
Lunch and refreshment breaks are included for all delegates in the exhibition hall on Monday and Tuesday. A ‘grab bag’ lunch will be available for delegates on Wednesday

**CLOAKROOM**
A cloakroom is available for delegate use in the main reception area.

**CME/CPD**
CPD approval has been sought from the Federation Royal Colleges of Physicians. Delegates can only record the actual number of hours attended for CME/CPD purposes.
PENS
Kindly sponsored by Lilly UK

PRE-REGISTRATION
‘Meet and Greet’ Reception Sunday 26 April 18.00 – 19.00
Foyer, Brighton Convention Centre.

POSTER DISPLAY AND JUDGING EXHIBITION HALL
Monday 13.15 – 13.45 Posters P1 – P52
Tuesday 13.15 – 13.45 Posters P53 – P114

PRIZES FOR PROFFERED PAPERS AND POSTERS

ORAL PRESENTATION
1st £300 plus President’s Cup Sponsored by Philips
2nd £150 Sponsored by Philips
3rd £50 Sponsored by Philips

POSTER PRESENTATION
1st        £300
2nd       £150
3rd        £50

CLINICAL PRACTITIONER ORAL
£300 Provided by an educational grant from Mallinckrodt

CLINICAL PRACTITIONER POSTER
£300 Provided by an educational grant from Mallinckrodt

MULTIMODALITY ORAL PRIZE
£350 Sponsored by Hermes

MULTIMODALITY POSTER PRIZE
£250 Sponsored by Hermes

RADIOPHARMACY ORAL PRIZE
£300 Sponsored by Alliance Medical

RADIOOTHERAPY PRIZE NEW FOR 2015
1st £300 Sponsored by Bayer
2nd £150 Sponsored by Bayer
3rd £50 Sponsored by Bayer

STUDENT PRIZE
1st £100 and free registration awarded by BNMS on abstract submission alone
2nd and 3rd Prize winners receive a certificate

REGISTRATION DESK OPENING TIMES
For Boot Camp 12.00 Sunday 26th April.
For Main Meeting:
Sunday Preregistration and ‘Meet and Greet’ Reception at 18.00
Monday 8.30 – 18.00
Tuesday 8.30 – 18.00
Wednesday 8.30 – 12.00

SPECIAL INTEREST GROUPS
Monday
12.20 - 13.00 Clinical Scientists Forum - Syndicate 2
14.00 - 14.45 Clinical Practitioner Group AGM Meeting Room 5
16.00 - 16.45 Medics forum Meeting Room 5

Tuesday
12.12-13.00 Radiopharmaceutical Sciences Group AGM - Syndicate 2
15.45-16.15 Trainees Forum - Syndicate 2
17.00 - 18.00 BNMS Members AGM - Auditorium 2

SOCIAL MEDIA
Follow us on Twitter @BNMSnews #BNMS2015 #BNMSbootcamp #BNMSbrighton

SOCIETY MEMBERSHIP
Membership of the British Nuclear Medicine Society is open to those who have a substantial interest and involvement in the development and provision of Nuclear Medicine services. The Society exists to further the professional, scientific and clinical interests of members and to support the development of Nuclear Medicine for the benefit of patients.

SUBSCRIPTION RATES
UK Full member £132
Overseas Full member £172
Full member reduced rate £108
Associate Member £60

Further details are available at the Conference Registration Desk or by visiting our website (www.bnms.org.uk)

WIFI
WiFi is available throughout the conference venue.
The first diagnostic PET tracer licensed for imaging beta-amyloid plaque density in adult patients undergoing evaluation for Alzheimer’s disease and other causes of cognitive impairment.

- **Amyvid PET scans** are interpreted using a binary visual read methodology (negative/positive).

- **ACCURATE**: 92% sensitivity (95% CI: 78% to 98%) and 100% specificity (95% CI: 80% to 100%) for detection of cortical neuritic plaque density (based on the majority of a blinded PET reading by 5 nuclear medicine physicians).

- **EFFECTIVE**: Amyvid and autopsy results agree.

- **RELIABLE**: Demonstrated inter-reader reproducibility.

- **FAVOURABLE TOLERABILITY AND CONVENIENCE FOR YOUR PATIENTS**: No fasting or glucose monitoring is required.

**OFFERS AN EFFICIENT IMAGING EXPERIENCE**

- After Amyvid is injected, there is a 30- to 50-minute uptake period.

- **AN AMYVID PET SCAN TAKES 10 MINUTES**

- **NEGATIVE SCAN**
  - Indicates sparse or no density of cortical beta-amyloid plaques.
  - Is not consistent with a diagnosis of AD.

- **POSITIVE SCAN**
  - Indicates moderate to frequent density of cortical beta-amyloid plaques.
  - Does not independently establish a diagnosis of AD or other cognitive disorder since neuritic plaque deposition in grey matter may be present in asymptomatic elderly and some neurodegenerative dementias (AD, Lewy body dementia, Parkinson’s disease dementia).

Please visit the Lilly Exhibit Booth # 16 for additional information.
AMYVID™ (FLORBETAPIR [18F]) ABBREVIATED PRESCRIBING INFORMATION

Due to the complex nature of radiolabelled diagnostic agents, please refer to the Summary of Product Characteristics and package information before prescribing or administering. These include guidance for storage, handling, and interpretation of the resulting positron emission tomography (PET) scans. Amyvid images should only be interpreted by readers trained in the interpretation of PET images with florbetapir (18F). With regard to interpreting the images, Reader Training is available.

Presentation Amyvid 800 MBq/ml: Each ml of solution for injection contains 800 MBq of florbetapir (18F) at the date and time of calibration (ToC) (ranges from 800 MBq to 12000 MBq). Multidose vials of 10 or 15 ml. Amyvid 1900 MBq/ml: Each ml of solution for injection contains 1900 MBq of florbetapir (18F) at the date and ToC (ranges from 1900 MBq to 28500 MBq). Multidose vials of 10 or 15 ml. Also contains ethanol, and sodium (up to 37 mg). Uses Diagnostic use only. Radiopharmaceutical indicated for PET imaging of β-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment. Amyvid should be used in conjunction with a clinical evaluation.

Dosage and Administration A PET scan with florbetapir (18F) should be requested by physicians skilled in the clinical management of neurodegenerative disorders. Amyvid images should only be interpreted by readers trained in the interpretation of PET images with florbetapir (18F). A recent co-registered computed tomography (CT) scan or magnetic resonance (MR) imaging of the patient to get a fused PET-CT or PET-MR image is recommended in cases of uncertainty about the location of grey matter and of the grey/white matter border in the PET scan. The recommended activity for an adult weighing 70 kg is 370 MBq florbetapir (18F). The volume of the injection should not be less than 1 ml and not exceed 10 ml. Elderly: Dosage adjustment not required. Renal and hepatic impairment: Careful consideration of the activity to be administered is required since an increased radiation exposure is possible in these patients. The pharmacokinetics of florbetapir (18F) in patients with renal or hepatic impairment have not been characterised. Florbetapir (18F) is excreted primarily through the hepatobiliary system and patients with hepatic impairment have the potential of increased radiation exposure. Method of administration: For intravenous use. For multidose use. The activity of florbetapir (18F) has to be measured with an activimeter (dose calibrator) immediately prior to injection. The dose is administered by intravenous bolus injection, followed by a flush of sodium chloride 9mg/ml (0.9%) solution for injection to ensure full delivery of the dose. Injection of Amyvid through a short intravenous catheter (approximately 4 cm or less) minimises the potential for adsorption of the active substance to the catheter. The injection of florbetapir (18F) must be intravenous in order to avoid irradiation as a result of local extravasation, as well as imaging artefacts. Image acquisition: A 10 minute PET image should be acquired starting approximately 30 to 50 minutes after intravenous injection of Amyvid. Patients should be supine with the head positioned to centre the brain, including the cerebellum, in the PET scanner field of view. Reducing head movement with tape or other flexible head restraints may be employed. Reconstruction should include attenuation correction with resulting transaxial pixel sizes between 2.0 and 3.0 mm. Contra-indications Known hypersensitivity to any ingredient. Warnings and Special Precautions Individual benefit/risk justification: For each patient, the radiation exposure must be justifiable by the likely benefit. The activity administered should, in every case, be as low as reasonably achievable to obtain the required diagnostic information. Limitations of use: A positive scan does not independently establish a diagnosis of AD or other cognitive disorder since neuritic plaque deposition in grey matter may be present in asymptomatic elderly and some neurodegenerative dementias (Alzheimer’s disease, Lewy body dementia, Parkinson’s disease, dementia). The efficacy of Amyvid for predicting development of AD or monitoring response to therapy has not been established. After the procedure: Close contact with infants and pregnant women should be restricted during the initial 24 hours following the injection. This medicinal product contains 10 vol % ethanol (alcohol), ie, up to 790 mg per dose, equivalent to 20 ml beer or 8 ml wine per dose. Interactions In vitro binding studies have not shown interference of florbetapir (18F) binding to β-amyloid plaques in the presence of other common medicinal products taken by AD patients. Fertility, Pregnancy, and Lactation The risk benefit ratio needs to be assessed on a case by case basis. Driving, etc Not relevant. Undesirable Effects Adverse reactions have been collected in clinical studies involving 555 subjects and 665 administrations of Amyvid solution for injection. No serious adverse reactions related to Amyvid administration have been reported. While they may in reality occur at lower frequencies than indicated below, the size of the source database did not allow for the assignment of frequency categories lower than the category “uncommon” (≥1/1000 to <1/100). Very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1000 to <1/100). Common: Headache. Uncommon: Dysgeusia, flushing, nausea, pruritus, urticaria, infusion site reactions including rash, haemorrhage, irritation, and pain. Other Information Shelf life: 800 MBq/ml is 7.5 hours, 1900 MBq/ml is 10 hours, from the ToC. Each vial is enclosed in a shielded container of appropriate thickness to minimise external radiation exposure. Product does not require any special temperature storage conditions. Storage of radiopharmaceuticals should be in accordance with national regulation on radioactive materials. For full details of these and other side-effects, please see the Summary of Product Characteristics, which is available at http://emc.medicines.org.uk/. Legal Category POM Marketing Authorisation Numbers EU/1/12/805/001 800 MBq/ml, 1–10 ml - 1 vial EU/1/12/805/002 800 MBq/ml, 1–15 ml - 1 vial EU/1/12/805/003 1900 MBq/ml, 1–10 ml - 1 vial EU/1/12/805/004 1900 MBq/ml, 1–15 ml - 1 vial Basic NHS Cost £810/370 MBq. Date of Preparation or Last Review August 2013 Full Prescribing Information is Available From Eli Lilly and Company Limited Lilly House, Priestley Road Basingstoke, Hampshire, RG24 9NL Telephone: Basingstoke (01256) 315 000 E-mail: ukmedinfo@lilly.com Website: www.lilly.co.uk AMYVID™ (florbetapir [18F]) is a trademark of Eli Lilly and Company.

UKAMY00103a(1) March 2015

Adverse events should be reported. Reporting forms and further information can be found at: www.mhra.gov.uk/yellowcard.

Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.

Professor Homer A. Macapinlac
James E. Anderson Distinguished Professor & Chair, Department of Nuclear Medicine University of Texas M.D. Anderson Cancer Center Houston, Texas
Dr. Homer A. Macapinlac is the James E. Anderson Distinguished Professor of Nuclear Medicine and Chair of the Department of Nuclear Medicine at the University of Texas M.D. Anderson Cancer Center in Houston, Texas and holds a joint appointment in the Department of Cancer Systems Imaging. Prior to joining M.D. Anderson, he served as clinical director of the Laurent and Alberta Gershel PET Center, served as Chief Resident for the Nuclear Medicine service, and completed his Oncologic Imaging and PET fellowship all at Memorial Sloan-Kettering Cancer Center (MSKCC), in New York. Dr. Macapinlac is an active committee member of various groups and societies and is an expert consultant for the International Atomic Energy Agency. He has over 170 publications and is considered a national and international expert in the field of nuclear medicine and positron emission tomography. Dr. Macapinlac is board certified by the American Board of Nuclear Medicine, with a Certificate of Added Qualification (CAQ) in Nuclear Cardiology. He was also elected as a fellow of the American College of Nuclear Physicians. He was past-President of the Society of Nuclear Medicine PET Center of Excellence and received the SNM Distinguished Service Award for this role. He was selected as the recipient of the 2014 Vikram Sarabhai Oration Award from the Society of Nuclear Medicine India.

Dr K.G.Kallur
Director Molecular Imaging
Healthcare Global Enterprises Ltd, Bangalore, Karnataka, India
Dr K.G.Kallur Educational Qualification: MBBS, DRM, MD Experience: Total 26 years. Worked as Lecturer and Assistant Professor of Nuclear Medicine in various teaching institutions in India. Currently working as 1. Head of Nuclear Medicine department at Bangalore Institute of Oncology and HCG in Bangalore from 1996 till date. 2. Professor and Head of Nuclear Cardiology division at Sri Jayadeva Institute of Cardiology Bangalore from 1999. Established India's first cGMP cyclotron and PET tracer production facility in the year 2007. Currently doing about 800 PET-CT scans per month and approximately 200 Non FDG PET-CT scans per month. Established Nuclear Medicine therapy and currently doing about 8-10 I-131 therapies for Carcinoma Thyroid and 5-6 PRRT for NET. Professional affiliations: 1. Member of SNM India and SNMMI, EANM 2. Founder member ANMPI [Association of Nuclear Medicine Physicians of India 3. Past President of Southern Chapter of SNM India. 4. President ANMPI for the year 2010-12 Area of interest: Radiopharmacy

Dr Renato Valdãs Olmos
Senior Consultant In Nuclear Medicine Netherlands Cancer Institute and Leiden University Medical Centre
Renato Valdãs Olmos (MD, PhD) is Senior Consultant in Nuclear Medicine at the Netherlands Cancer Institute “Antoni van Leeuwenhoek Hospital, and since October 2012 at the Leiden University Medical Centre concerning Interventional Molecular Imaging and Nuclear Medicine Section activities. Since 1993 he is involved in
lymphatic mapping, radioguided surgery and the sentinel node procedure. He is founding member of the International Sentinel Node Society and currently member of its board. Involved in various projects concerning sentinel node identification using hybrid modalities for radioactivity/fluorescence detection, he is also one of the leaders of an Eurostars innovation project concerning 3D radioguided breast tumour excision and surgical navigation as well as of a EU project concerning evaluation of a dedicated PET ring device for ¹⁸F-FDG guided biopsy in breast cancer (MAMMOCARE).

“Radioiodine therapy in thyroid cancer: Indian Perspective”
Monday 11.30-12.00 AUDITORIUM 2
MASTER CLASS 2: RADIONUCLIDE THERAPY SESSION

Dr Partha Choudhury
Director (Nuclear Medicine)
Rajiv Gandhi Cancer Institute & Research Centre Delhi India


“Axillary Reverse Mapping - A concept towards preventing lymphedema”
Monday 15.10-15.30 AUDITORIUM 2
MASTER CLASS 3: SENTINEL NODE IMAGING: FUSION OF LIGHT AND SOUND SESSION

Prof Shanmuga Sundaram P
Clinical Professor
Amrita Institute of Medical Sciences University, Cochin, Kerala, India


Initially worked as Asst professor, Nuclear medicine at S.V Institute of medical sciences, Tirupati. Later joined Amrita Institute of Medical sciences (under Amrita vishwa Vidyaapeetham University), Cochin, Kerala, India from 2000 till date as Clinical Professor in Nuclear medicine & PET-CT. President elect (2015-17) of Association of Nuclear medicine physicians of India.

Started DNB (Diplomate of national board) Nuclear medicine training programme in our institute in 2006. Ours was the first institute to be accorded MD Nuclear medicine programme under Medical council of India in 2011.

Attended fellowship programmes in PET-CT imaging at Katherine Hospital, Stuttgart, Germany and also at Peter Mac Callum cancer
centre, Melbourne, Australia. I am an active member of Society of Nuclear medicine India, ANMPl, and also of European society of Nuclear medicine, and American society of nuclear cardiology. Achievements: Recipient of young investigator awards from Indo American society of Nuclear medicine IASNM in 2002 in Los Angeles, USA, Multiple Travel grant awards from European society of Cardiology 2005, 2007 & 2013, ARCCNM 2005, WFNMB at Seoul, South Korea 2006 and IAEA 2007, 2011. I have 92 national & international publications to my credit apart from contributing to books in Nuclear medicine.

“Salivagram - A sensitive investigation in the evaluation of antegrade aspiration”
Monday 16.15-16.45 SYNDICATE 1&2
BONE SPECT & ENDOCRINE HEPATOBILIARY SESSION

DR S. Padma
Clinical Professor
Amrita Institute of Medical Sciences Univerity, Cochin, Kerala, India

Completed medical graduation (MBBS) in 1990 from SCB Medical College, Cuttack, Odisha, India and postgraduation in Nuclear medicine in 1995 from Radiation medicine centre, Tata Memorial hospital, BARC, Bombay, India. Initially worked at Nuclear medicine centres in Port trust hospital, Mumbai and S.V Institute of medical sciences, Tirupati. Joined Amrita Institute of Medical sciences (under Amrita vishwa Vidyapeetham University), Cochin, Kerala, India in the year 2000 and presently serving as a Clinical Professor in Department of Nuclear medicine & PET-CT in the same institute. Past President of Society of Nuclear medicine India, south chapter 2006 - 08. Teacher and guide to DNB (Nuclear med) and MD Nuclear medicine students. Published 89 scientific papers, review articles, and chapters in books on Nuclear medicine. Recipient of Arcot Gajaraj Best paper award from Society of Nuclear medicine India south chapter in the year 2000. Also received multiple young investigator and travel grant awards from international societies like European society of Cardiology (ICNC), Asian Regional Coop Council on Nuclear Medicine (ARCCCNM), International Atomic Energy Agency (IAEA) and World Federation of Nuclear medicine & biology (WFNMB). My extracurricular activities: classical Odissi dancer, completed postgraduation (MA) in Odissi dance from Kala vikas Kendra, Cuttack, Odisha 1987.

“Recent Advances in Instrumentation & Techniques”
Monday 16.00-16.30 AUDITORIUM 2
MASTER CLASS 3: SENTINEL NODE IMAGING: FUSION OF LIGHT AND SOUND SESSION

Dr Thomas Wendler
CTO & VP of Medical Affairs SurgicEye GmbH

Dr. Thomas Wendler is CTO & VP of Medical Affairs and one of the co-founders of SurgicEye GmbH. Dr. Wendler studied Electronic Engineering at Universidad Tecnica Federico Santa Maria (UTFSM) in Valparaiso, Chile. For his consistently excellent results, he received various accolades and Best Student of the Year awards. He completed his studies in the field of biomedical engineering at Technische Universitat Munchen (TUM) in Munich, Germany with the DAAD Best Student 2007 Award. In 2010 he closed with highest distinction his Ph.D. in medical imaging at TUM. Before his management activities at SurgicEye GmbH Dr. Wendler was responsible for the research field of Molecular Imaging at the Department for Computer Aided Medical Procedures at TUM. He had also a secondary appointment at the Nuclear Medicine Department at Klinikum rechts der Isar where he was responsible for the installment of the central interdisciplinary research laboratory. In 2006 he introduced and developed the concept of freehand molecular imaging opening new ways in radio-guided surgery and intervention.
BNMS Annual Awards Dinner
Each year the BNMS gathers to celebrate outstanding achievements in the contribution to the field of science and practice of nuclear medicine in the United Kingdom.

Now in its 43rd year, BNMS delegates are invited to enjoy a dinner and dance in the Paganini Room on the Tuesday 28th April at Old Ship Hotel, Brighton from 7.30pm till late.

Entertainment will be provided by The Abductors.
Tickets are £40 each. Please enquire at the registration desk for availability.

BNMS Fun Run 2015
With such a great response received from past meetings, the BNMS will be organising another 3K Charity Fun Run supporting Autism Sussex.

Make your own team from your hospital department or run solo and join us on the Brighton broad walk on Tuesday 28th April 7.30 am

All are encouraged to take part or cheer on the contenders at the finish line. Trophy for 1st place will be awarded on Tuesday.

BNMS Clinical Practitioner’s Group 25th Anniversary Celebration and President’s Reception
The BNMS Clinical Practitioner’s Group of Radiographers and Technologists will be celebrating its 25th anniversary at the BNMS Annual Spring Meeting in Brighton.

To commemorate this important landmark, all Clinical Practitioners are invited to apply for a free place to our proffered papers and invited speakers’ session on Monday 27th April at 3pm.

This will be followed by a celebratory cake at the President’s Reception. The celebrations will continue with a social gathering at the ‘Fortune of War’ pub from 8.00pm.

To register for social gathering please contact Katherine.Day@bsuh.nhs.uk
https://www.facebook.com/FortuneBrighton
MONDAY 27TH APRIL 08.50-8.55 AUDITORIUM 2
INAUGURATION OF THE BNMS 43RD ANNUAL SPRING MEETING
Dr. Alp Notghi, Birmingham City Hospital, BNMS President
Dr. Brian Neilly, Glasgow Royal Infirmary, Immediate Past President

TUESDAY 28TH APRIL 14.00-15.00 AUDITORIUM 2
ANNUAL LECTURE
“The Evolving Role of Clinical Molecular Imaging in Multi-Disciplinary Cancer Care”
Professor Homer A. Macapinlac
James E. Anderson Distinguished Professor & Chair, Department of Nuclear Medicine University of Texas M.D. Anderson Cancer Center Houston, Texas

WEDNESDAY 29TH APRIL AUDITORIUM 2 12.15-12.30
AWARDS CEREMONY

WEDNESDAY 29TH APRIL AUDITORIUM 2 12.30-13.15
HIGHLIGHTS OF THE BNMS 43RD ANNUAL SPRING MEETING
Dr. Brian Neilly, Glasgow Royal Infirmary, Immediate Past President
BOOTCAMP
CONVENTIONAL NUCLEAR MEDICINE & PET/CT: BEST PRACTICE CONSENSUS & HOW THE EXPERTS DO IT?

Syndicate 3

12.00-13.00 REGISTRATION IN FOYER AND COMPLIMENTARY BUFFET LUNCH IN SYNDICATE 1

13.00-15.00 PET/CT IN ONCOLOGY 1

15.00-15.30 Tea & Coffee in Exhibition Hall

15.30-18.00 PET/CT IN ONCOLOGY 2

18.00-19.30 PRE-REGISTRATION AND WELCOME RECEPTION IN FOYER

Syndicate 4

13.00-15.00 CONVENTIONAL NUCLEAR MEDICINE BEST PRACTICE CONSENSUS FOR CLINICAL PRACTITIONERS/TECHNOLOGISTS

Meeting Room

13.00-18.00 MOLECULAR RADIOTHERAPY TRAINING PRE-REGISTRATION REQUIRED.

15.00-15.30 Tea & Coffee in Exhibition Hall

18.00-19.00 PRE-REGISTRATION AND WELCOME RECEPTION IN FOYER
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.00</td>
<td>Tea &amp; Coffee in the Exhibition Hall</td>
</tr>
<tr>
<td>8.30</td>
<td>MASTERCLASS IV: LUNG CANCER</td>
</tr>
<tr>
<td>9.00</td>
<td>Tea &amp; Coffee in the Exhibition Hall</td>
</tr>
<tr>
<td>9.30</td>
<td>MASTERCLASS V: LYMPHOMA</td>
</tr>
<tr>
<td>10.00</td>
<td>Tea &amp; Coffee in the Exhibition Hall</td>
</tr>
<tr>
<td>10.30</td>
<td>Tea &amp; Coffee in the Exhibition Hall</td>
</tr>
<tr>
<td>11.00</td>
<td>Lunch &amp; Meet Industry in the Exhibition Hall</td>
</tr>
<tr>
<td>11.30</td>
<td>Lunch &amp; Meet Industry in the Exhibition Hall</td>
</tr>
<tr>
<td>14.00</td>
<td>ANNUAL LECTURE: &quot;THE EVOLVING ROLE OF CLINICAL MOLECULAR IMAGING IN MULTI-DISCIPLINARY CANCER CARE&quot;: PROFESSOR HOMER MACAPINLAC, MD ANDERSON CANCER CENTRE, THE UNIVERSITY OF TEXAS</td>
</tr>
<tr>
<td>15.00</td>
<td>Tea &amp; Coffee in the Exhibition Hall</td>
</tr>
<tr>
<td>15.30</td>
<td>Tea &amp; Coffee in the Exhibition Hall</td>
</tr>
<tr>
<td>15.45</td>
<td>TRAINEES FORUM - DEENA NERIMAN</td>
</tr>
<tr>
<td>16.00</td>
<td>Tea &amp; Coffee in the Exhibition Hall</td>
</tr>
<tr>
<td>16.15</td>
<td>Tea &amp; Coffee in the Exhibition Hall</td>
</tr>
<tr>
<td>16.30</td>
<td>PET/CT CASE REVIEW: &quot;DEALING WITH THE CLINICAL CHAMELEON&quot;</td>
</tr>
<tr>
<td>16.45</td>
<td>ANNUAL LECTURE SESSION - VIDEO PRESENTATIONS AND INVITED TALK</td>
</tr>
<tr>
<td>17.00</td>
<td>BNMS ANNUAL GENERAL MEETING</td>
</tr>
<tr>
<td>17.30</td>
<td>Tea &amp; Coffee in the Exhibition Hall</td>
</tr>
<tr>
<td>18.00</td>
<td>Tea &amp; Coffee in the Exhibition Hall</td>
</tr>
</tbody>
</table>
AT A GLANCE PROGRAMME WEDNESDAY 29TH APRIL

AUDITORIUM 2

08.30-10.25 YOUNG INVESTIGATORS’ PRIZE

10.30-10.45 Tea & Coffee

10.45-12.15 NUCLEAR MEDICINE: MISCELLANEOUS INVITED SPEAKERS

12.15-12.30 AWARDS CEREMONY

12.30-13.15 HIGHLIGHTS LECTURE DR BRIAN NEILLY

12.30-13.15 Lunch and Close of Meeting

SYNDICATE 3

08.30-10.30 RADIONUCLIDE THERAPY PROFFERED PAPERS

10.30-10.45 Tea & Coffee

SYNDICATE 4

8.30-10.30 NUCLEAR MEDICINE: MISCELLANEOUS PROFFERED PAPERS

10.30-10.45 Tea & Coffee

10.45-12.15 NUCLEAR MEDICINE: MISCELLANEOUS INVITED SPEAKERS

12.15-12.30 AWARDS CEREMONY

12.30-13.15 HIGHLIGHTS LECTURE DR BRIAN NEILLY

12.30-13.15 Lunch and Close of Meeting

NUCLEAR MEDICINE COMMUNICATIONS
FREE ONLINE ACCESS TO THE MAY ISSUE FOR ALL DELEGATES

All delegates can access the May edition of NMC containing the abstract booklet for BNMS Brighton 2015 via the website: www.nuclearmedicinecomm.com. or via the QR code.

NMC - A monthly rapid communications journal publishing research and clinical work in all areas of nuclear medicine for an international readership. In addition to refereed papers, the journal features frankly written editorials, topical reviews, book reviews and reporting of international conferences.

NMC is the official Journal of the British Nuclear Medicine Society. Full access to the online version of Nuclear Medicine Communications is included in the BNMS membership fee.

NMC is now available via an app for iPad for all members. Join the BNMS for full access to NMC. Find out more from the BNMS registration desk.
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.00</td>
<td><strong>REGISTRATION IN FOYER AND COMPLIMENTARY BUFFET LUNCH IN SYNDICATE 1</strong></td>
</tr>
<tr>
<td>13.00-15.00</td>
<td><strong>PET/CT IN ONCOLOGY 1</strong></td>
</tr>
<tr>
<td>13.00-13.30</td>
<td>Overview of PET/CT Applications in Gynaecological Malignancies.</td>
</tr>
<tr>
<td></td>
<td>Dr Tara Barwick Imperial College Healthcare NHS Trust</td>
</tr>
<tr>
<td>13.30-14.00</td>
<td>Overview of Neuro-Oncology PET/CT/MRI Applications</td>
</tr>
<tr>
<td></td>
<td>Dr Francesco Frielani University College London Hospitals</td>
</tr>
<tr>
<td>14.00-14.30</td>
<td>Overview of PET/CT in management of Breast Cancer.</td>
</tr>
<tr>
<td></td>
<td>Dr Nagesh Nagabhushan</td>
</tr>
<tr>
<td>14.30-15.00</td>
<td>Overview of PET/CT Applications in Melanoma.</td>
</tr>
<tr>
<td></td>
<td>Dr Andrew Scarsbrook Leeds Teaching Hospitals NHS Trust</td>
</tr>
<tr>
<td>15.00-15.30</td>
<td>Tea &amp; Coffee in Syndicate 1</td>
</tr>
<tr>
<td>13.00-15.00</td>
<td><strong>PET/CT IN ONCOLOGY 2</strong></td>
</tr>
<tr>
<td>13.00-14.15</td>
<td>Physical requirements of radiopharmaceuticals used for MRT and their biokinetics</td>
</tr>
<tr>
<td></td>
<td>Dr Redpath Imperial College Healthcare NHS Trust</td>
</tr>
<tr>
<td>14.00-14.45</td>
<td>Appropriate selection and operation of radiation monitors and detectors</td>
</tr>
<tr>
<td>14.30-15.00</td>
<td>Role of PET/CT in Dementia.</td>
</tr>
<tr>
<td></td>
<td>Dr Zarni Win Imperial College NHS Trust</td>
</tr>
<tr>
<td>17.00-17.30</td>
<td>PET/CT Protocols: Patient Pathway:</td>
</tr>
<tr>
<td></td>
<td>Dr Teresa Szyszko PET Imaging Centre at St Thomas’ Hospital London</td>
</tr>
<tr>
<td>17.30-18.00</td>
<td>Structured PET/CT reporting: Challenges &amp; solutions.</td>
</tr>
<tr>
<td></td>
<td>Dr Simon Hughes Nottingham University Hospitals NHS Trust</td>
</tr>
<tr>
<td>18.00-19.30</td>
<td>PRE-REGISTRATION &amp; WELCOME RECEPTION FOYER</td>
</tr>
<tr>
<td>13.00-18.00</td>
<td><strong>MOLECULAR RADIOTHERAPY TRAINING</strong></td>
</tr>
<tr>
<td>13.00-14.15</td>
<td>Kindly Sponsored by Hermes Medical Solutions</td>
</tr>
<tr>
<td></td>
<td>AV sponsored by the National Physical Laboratory</td>
</tr>
<tr>
<td>14.00-14.45</td>
<td><strong>REGISTRATION IN FOYER AND COMPLIMENTARY BUFFET LUNCH IN SYNDICATE 1</strong></td>
</tr>
<tr>
<td>13.00-15.00</td>
<td><strong>CONVENTIONAL NUCLEAR MEDICINE: BEST PRACTICE CONSENSUS FOR CLINICAL PRACTITIONER/TECHNOLOGISTS</strong></td>
</tr>
<tr>
<td></td>
<td>Moderators Lloyd Rowling &amp; Samera Bangash</td>
</tr>
<tr>
<td></td>
<td>Dr Gregory Shabo East Kent Hospitals University NHS Foundation Trust</td>
</tr>
<tr>
<td></td>
<td>Dr Lorenzo Biassoni Great Ormond Street Hospital for Children NHS Foundation Trust</td>
</tr>
<tr>
<td></td>
<td>Ian Armstrong, Central Manchester University Hospitals</td>
</tr>
<tr>
<td>14.30-15.00</td>
<td>Patient preparation for PET/CT: Challenges &amp; solutions.</td>
</tr>
<tr>
<td></td>
<td>Joemon John Clinical PET centre, Guys &amp; St Thomas NHS Hospital</td>
</tr>
<tr>
<td>18.00-19.30</td>
<td>PRE-REGISTRATION &amp; WELCOME RECEPTION FOYER</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>14.45-16.30</td>
<td><strong>Session 2</strong></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>16.30-17.00</td>
<td><strong>Tea &amp; Coffee</strong></td>
</tr>
<tr>
<td>17.00-18.00</td>
<td><strong>Session 3</strong></td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
</tr>
<tr>
<td>----------</td>
<td>------------------------------------------------</td>
</tr>
<tr>
<td>08.50-08.55</td>
<td>INAUGURATION</td>
</tr>
<tr>
<td>09.00-10.30</td>
<td>MASTER CLASS 1: PET/MRI</td>
</tr>
<tr>
<td>09.00-09.30</td>
<td></td>
</tr>
<tr>
<td>09.30-10.00</td>
<td></td>
</tr>
<tr>
<td>10.00-10.30</td>
<td></td>
</tr>
<tr>
<td>10.30-11.00</td>
<td>Tea &amp; Coffee in the Exhibition Hall</td>
</tr>
<tr>
<td>11.00-13.00</td>
<td>MASTER CLASS 2: RADIONUCLIDE THERAPY</td>
</tr>
<tr>
<td>11.00-11.30</td>
<td></td>
</tr>
<tr>
<td>11.30-12.00</td>
<td></td>
</tr>
<tr>
<td>12.00-12.30</td>
<td></td>
</tr>
<tr>
<td>12.30-13.00</td>
<td></td>
</tr>
<tr>
<td>13.00-14.00</td>
<td>Lunch &amp; Meet Industry in the Exhibition Hall</td>
</tr>
<tr>
<td>13.15-13.45</td>
<td>Moderated Poster Session</td>
</tr>
<tr>
<td>14.00-16.30</td>
<td>MASTER CLASS 3: SENTINEL NODE IMAGING: FUSION OF LIGHT AND SOUND</td>
</tr>
<tr>
<td>14.00-14.30</td>
<td></td>
</tr>
<tr>
<td>14.30-14.50</td>
<td></td>
</tr>
<tr>
<td>14.50-15.10</td>
<td>SNI node excision in Malignant Melanoma: Surgeons Perspective Beyond Hot Spots</td>
</tr>
<tr>
<td>15.10-15.30</td>
<td></td>
</tr>
<tr>
<td>15.30-16.00</td>
<td></td>
</tr>
<tr>
<td>16.00-16.30</td>
<td></td>
</tr>
<tr>
<td>16.30-17.00</td>
<td>Tea &amp; Coffee in the Exhibition Hall</td>
</tr>
<tr>
<td>17.00-18.00</td>
<td>NUCLEAR MEDICINE: THE CHANGING LANDSCAPE</td>
</tr>
<tr>
<td>17.00-17.30</td>
<td></td>
</tr>
<tr>
<td>17.30-18.15</td>
<td></td>
</tr>
<tr>
<td>18.15-19.45</td>
<td></td>
</tr>
<tr>
<td>08.50-08.55</td>
<td>INAUGURATION</td>
</tr>
<tr>
<td>08.55-10.30</td>
<td>PROFFERED PAPERS PET/CT &amp; PET/MRI</td>
</tr>
<tr>
<td>08.54-09.06</td>
<td></td>
</tr>
</tbody>
</table>
09.06-09.18 35. 18FDG-PET-CT Sheds New Light in the Clinical Management of Richter’s Transformation from Chronic Lymphocytic Leukaemia (CLL)
Y Du, The Royal Marsden NHS Foundation trust, Sutton, UK

09.18-09.30 36. Eight Years of Experience with 68Ga-DOTATATE PET-CT Imaging in Neuroendocrine Tumours
E. Skoura, E. Fanagiotidis, M. Al-Harb, I. Kayani, R. Syed, M.E. Caplin and J. Bomanji, Nuclear Medicine Department, University College Hospital and 2Neuroendocrine Tumour Unit, Royal Free Hospital, London, UK

09.30-09.42 37. Impact of Dietary Carbohydrate Restriction Prior to 18F-FDG PET-CT for Suspected Cardiac Implantable Electronic Device (CIED) Infection and Endocarditis.
JM James, M Memmott, F Ahmed, Nuclear Medicine Centre, Central Manchester NHS Foundation Trust, Manchester, UK, 2Department of Cardiology, Central Manchester NHS Foundation Trust, Manchester, UK

09.42-09.54 38. Segmentation Based Attenuation Correction for PET/MR: Artifacts and Pitfalls
S Michopoulou, A Barnes, D Brown, S Burns, JC Dickson, Institute of Nuclear Medicine, University College London Hospitals, London, UK

09.54-10.06 39. The Clinical Value of 18F-FDG PET-CT in the Diagnosis of Large-Vessel Vasculitis: A District General Hospital Experience
B Clarke, R Masiay, H Linklater, S Patel, A Parthipun, Epsom & St Helier University Hospitals NHS Trust, Surrey, UK

10.06-10.18 40. Benefit of Wholebody Quantification of 18F-Fluoride PET Images Over Target Lesion Analysis Alone For Prognostication For Patients With Bone Metastases From Metastatic Prostate Cancer.
B Taylor, S Hughes, M Siddique, J Joemon, I Fogelman, S Chowdhury, V Goh, GJ Cook, Guy’s & St Thomas’ NHS Foundation Trust, London, UK, 2King’s College London, London, UK

10.18-10.30 41. Combining A weight-Based Dosing Scheme With Time-of-Flight For Further Reductions In Patient and Staff FDG Doses
IS Armstrong, JM James, S Muthu, Central Manchester University Hospitals, Manchester, UK

10.30-11.00 Tea & Coffee in the Exhibition Hall

11.00-13.00 PHYSICS: PROFFERED PAPERS

11.00-13.00 Chairs Prof Alan Perkins and Maria Burniston

11.00 -11.12 42. A Method to Identify Periods of Minimal Patient Motion in Florbetapir (18F) (Amyvid) PET-CT Scans
D Fakhry-Darian, R T Meades, L Perry, B Williams, Z Win, K S Nijran
1Radiological Sciences Unit, Imperial College Healthcare NHS Trust, London, UK, 2Nuclear Medicine, Imperial College Healthcare NHS Trust, London, UK

11.12-11.24 43. Poisson Resampling Software Validation
G James, J O’Brien, WH Thomson, City Hospital, Birmingham, UK


11.36-11.48 45. The Effect of Attenuation and Scatter Correction In Brain Perfusion SPECT Imaging For Dementia
R Gillen, M J Firbank, J Lloyd, J T O’Brien, South of Tyne Medical Physics Department, City Hospitals Sunderland, Tyne and Wear, UK, 2Nuclear Medicine Department, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK, 3Institute of Neuroscience, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UK, 4Department of Psychiatry, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK

11.48-12.00 46. SeHCAT Room vs. Patient Background: Which is better?
G James, J O’Brien, WH Thomson, City Hospital, Birmingham, UK

12.00-12.12 47. Optimisation of 90Y post-SIRT PET Imaging Using a Novel PET Reconstruction Algorithm

12.12-12.24 48. A Comparison of Lung Tumour Motion as Determined by *DCT and Data Driven Gating of PET-CT
S Woods, P Julyan, The Christie NHS Foundation Trust, Manchester, UK

12.24-13.00 Clinical Scientist Forum

13.00-14.00 Lunch & Meet Industry in the Exhibition Hall

13.15-13.45 Moderated Poster session

14.00-16.00 AMYVID™ (FLORBETAPIR 18F) PET IMAGING READER TRAINING
Dr Simon Hughes, Consultant in Radiology and Nuclear Medicine, Nottingham University Hospital
Eli Lilly and Company LTD have sponsored the content of this session

16.00-16.30 Tea & Coffee

16.00-18.00 AMYVID™ (FLORBETAPIR 18F) PET IMAGING READER TRAINING CONTINUED

18.15-19.45 PRESIDENT’S RECEPTION - EXHIBITION HALL
### SYNDICATE 3

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.50-08.55</td>
<td>INAUGURATION</td>
</tr>
<tr>
<td>09.00-10.30</td>
<td>PHYSICS : INVITED REVIEW &amp; PROFFERED PAPERS</td>
</tr>
<tr>
<td>09.00-09.30</td>
<td>Streamlining Administered Activity, Scanning Time for PET with TOF systems.</td>
</tr>
<tr>
<td>09.30-09.42</td>
<td>1. Optimisation of Myocardial Perfusion SPECT Using LEGP Collimators and Resolution Recovery</td>
</tr>
<tr>
<td>09.42-09.54</td>
<td>2. Role of Factor Analysis in the Automatic Evaluation of Radionuclide Images</td>
</tr>
<tr>
<td>10.06-10.18</td>
<td>3. Comparison of $^{99m}$Tc-MAA and $^{99m}$Y-Microsphere Distributions</td>
</tr>
<tr>
<td>10.18-10.30</td>
<td>4. K-Means Clustering Algorithm for Delineation of The Liver For Microsphere Therapy Dosimetry</td>
</tr>
<tr>
<td>10.30-11.00</td>
<td>Tea &amp; Coffee in the Exhibition Hall</td>
</tr>
<tr>
<td>11.00-13.00</td>
<td>CARDIOLOGY : INVITED REVIEW &amp; PROFFERED PAPERS</td>
</tr>
<tr>
<td>11.00-11.30</td>
<td>IRb Cardiac PET imaging: Hurdles of defending the service.</td>
</tr>
<tr>
<td>11.30-12.00</td>
<td>Nuclear Cardiology: The next decade.</td>
</tr>
</tbody>
</table>

### 12.00-12.12

6. Reducing $^{99m}$Tc usage in Myocardial Perfusion SPECT in Preparation for Future Isotope Shortages  
IS Armstrong, KJ Saint, CM tonge, P Arumugam, Central Manchester University Hospitals, Manchester, UK

### 12.12-12.24

7. Is early exercise $^{99m}$Tc-Sestamibi Myocardial Perfusion Scintigraphy Feasible?  
E Papadopoulos, V Sachpektis, GA Wright, AC Tweddell, Hull and East Yorkshire Hospitals NHS Trust, Cottingham, East Yorkshire, UK

### 12.24-12.36

8. Perfusion-corrected $^{99m}$Tc-MIBI for the Identification of Cardiac Mitochondrial toxicity  
S. Safae, P.J Blower, R. Southworth, Kings College London, London, UK

### 12.36-12.48

9. Truncation Artefacts in Computed Tomography (CT) Attenuation Correction (AC) for Myocardial Perfusion Studies (MPS)  
A. O'Brien, A. Notghi, GD James, WH Thomson, Sandwell & West Birmingham Hospitals NHS Trust, West Midlands, UK

### 12.48-13.00

10. Modelling a Local Acute 7-Day Nuclear Cardiology Service Demonstrates a Financial Benefit In Managing Acute Coronary Syndromes (ACS) In A UK NHS Trust  
K Day, N Singh, S Dizdarevic, Brighton and Sussex University Hospitals Trust, Brighton, East Sussex, UK

### 13.00-14.00

Lunch & Meet Industry in the Exhibition Hall

### 13.15-13.45

Moderated Poster session

### 14.00-15.30

ONCOLOGY: INVITED REVIEW & PROFFERED PAPERS

### 14.00-14.30

Tumour Heterogenity: Science & Clinical Application  
Prof Gary Cook King's College London

### 14.30-14.42

11. FGD PET-CT Imaging of Nodal Metastases Distribution In Nasopharyngeal Carcinoma (NPC)  
A. Al Tamimi1, S Zaheer1, S Osmany2, A. Tamin, T. Massesachusetts General Hospital/Harvard Medical School, Boston, USA, 1Radiology and PET Imaging, Singapore, Singapore, 2Singapore General Hospital, Singapore, Singapore

### 14.42-15.45

12. Heterogeneity of Treatment Response In Skeletal Metastases From Breast Cancer in 18F-fluoride and 18F-FDG PET.  
GJ Cook1, BP Taylor1, J Glendenning1, M Siddique1, J John1, V Goh1, J Mansi2, M Harries1, I Fogelman1, 1Kings College London, London, UK, 2Guys & St Thomas' NHSFT, London, UK
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 14.54-15.06  | 13. 99mTc-Sestamibi Molecular Breast Imaging Guided Stereotactic Needle Biopsy of Radiologically Occult Breast Lesions  
LM Pereira Arias-Bouda1,2, F Smit1,2, P Neijenhuis1, LMH Wijers1, AF van der Hoeven1,  
K Hofkes-Fillekes1, A Zeillemaker1, RA Valdes Olmos2,  
1Rijnland Hospital, Leiderdorp, The Netherlands, 2Leiden University Medical Center, Leiden, The Netherlands |
| 15.06-15.18  | 14. Predicting Neoadjuvant Chemotherapy Response In Oesophageal Cancer From Pretreatment 18F-FDG PET Using A Deep Neural Network Model.  
GJ Cook1, PP Ypsilantis1, HM Sohn1, M Siddique1, A Davies1, V Goh1, G Montana1  
1Kings College London, London, UK, 2Guys & St Thomas’ NHSFT, London, UK |
| 15.18–15.30  | 15. Management Decision: Role of 68Ga-DOTATATE PET-CT imaging in patients’ with Neuroendocrine Tumours  
E Skoura1, E Panagiotidis1, M Al-Harbi1, I Kayani1, R Syed1, ME Caplin2, J Bomanji1  
1Nuclear Medicine Department, University College Hospital, London, UK, 2Neuroendocrine Tumour Unit, Royal Free Hospital, London, UK |
| 15.30-16.00  | Tea & Coffee in the Exhibition Hall                                     |
| 16.00-18.24  | BONE SPECT & ENDOCRINE HEPATOBILIARY  
Chairs Dr Raghuveer Venkannagari & Dr N Mulholland |
| 16.00-16.30  | Salivagram - A sensitive investigation in the evaluation of antegrade aspiration  
Dr S Padma Amrita Institute of Medical Sciences University. Cochin, Kerala, India |
| 16.30-17.00  | Gastric Emptying Studies, Science and Practice  
Prof Alan Perkins Nottingham University Hospitals NHS Trust, Nottingham |
| 17.00-17.12  | 16. The Role of 99mTc MDP SPECT-CT of the Foot & Ankle  
B Upadhyay, KE Low, Z Saad, J Buscombe, Cambridge University Hospitals, Cambridge, UK |
| 17.12-17.24  | 17. The Additional Value of 18F Fluoride PET-CT Bone Scans Over Planar Bone Scintigraphy Using 99mTc MDP and Its Impact On Patient Management In Breast Cancer Patients  
R K Kulshrestha1,2, S Vinjamuri1,2, P Hogg1, A England1,  
1Central Manchester University Teaching Hospitals NHS Foundation Trust, Manchester, UK, 2Royal Liverpool University Teaching Hospitals NHS Foundation Trust, Liverpool, UK, 3University of Salford, Salford, UK |
| 17.24-17.36  | 18. A Comparison of Different Analysis Techniques for Temporomandibular Joint (TMJ) Bone Scans  
A-M Tutty, AA Bolster, G Ainslie-McLaren, C Paterson, H Wallace, J Wright, Dept. of Nuclear Medicine, Glasgow Royal Infirmary, Glasgow, UK |
| 17.36-17.48  | 19. Clinical Evaluation of Xspect Reconstruction For 99mTc Diphosphonate SPECT Bone Imaging.  
L Vass, J Wallner, A Irwin, St George’s Healthcare NHS Trust, London, UK |
| 17.48-18.00  | 20. SPECT-CT In Patients With Symptomatic Knee Arthroplasty – Do Radiological Reports Correlate With Orthopaedic Clinical and Surgical Findings?  
R James, S Redman, R Graham, Royal United Hospital NHS Foundation Trust, Bath, UK |
| 18.00-18.12  | 21. Single Photon Emission Computed tomography (SPECT)-CT Imaging Localisation of Parathyroid Adenomas Preoperatively  
S Tomas Hernandez, J O’Brien, A Notghi, M Pandit, City Hospital, Birmingham, West Midlands, UK |
| 18.12-18.24  | 22. Dual Isotope Subtraction SPECT-CT in the Diagnosis of Primary Hyperparathyroidism  
A-M Tutty1, AA Bolster1, JH Neilly1, JW Poon1, D Colville1, J Shand2, S Han1,  
1Dept. of Nuclear Medicine, Glasgow Royal Infirmary, Glasgow, UK, 2Dept. of Nuclear Medicine, Stobhill Hospital, Glasgow, UK |
| 18.15-19.45  | PRESIDENT’S RECEPTION - EXHIBITION HALL                             |

**SYNDICATE 4**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.50-08.55</td>
<td>INAUGURATION</td>
</tr>
</tbody>
</table>
| 09.00-10.30  | CLINICAL PRACTITIONERS CONTINUING EDUCATION SERIES 1  
Chairs Lloyd Rowling & Katherine Day |
| 09.00-09.30  | Sentinel lymph node dissection in the Operating theatre: Surgical challenges.  
Dr Clare Schilling Guy’s Hospital, King’s College London |
| 09.30-10.00  | Nuclear Medicine Imaging of Hepatobiliary System  
Dr Nicola Mulholland King’s College Hospital |
| 10.00-10.30  | Nuclear Medicine and Oncology.  
Dr Francis Sundram University Hospital Southampton |
| 10.30-11.30  | Tea & Coffee in the Exhibition Hall                                     |
| 11.00-13.00  | CLINICAL PRACTITIONERS CONTINUING EDUCATION SERIES 2 :  
Chairs S Johns & Lloyd Rowling |
| 11.00-12.00  | CT Workshop for Nuclear Medicine Technologists– Part 1- (head/neck & thorax) |
| 12.00-13.00  | Read with the Experts (Physics, radiopharmacy, radiation protection): Interactive Quiz |
13.00-14.00  Lunch & Meet Industry in the Exhibition Hall
13.15-13.45  Moderated Poster session

15.00-16.00  CLINICAL PRACTITIONERS: INVITED TALKS & PROFFERED PAPERS
Chair Lloyd Rowling & Katherine Day
15.00-15.20  CT Competencies for NM Practitioners
Simon King, University of West of England, SCoR Nuclear
15.20-15.36  25 years of the BNMS Clinical Practitioner Group
Liz Clarke, GE Healthcare, Past-Chair, BNMS Clinical Practitioners’ Group.
Vicki Parkin, Mallinckrodt, Past-Chair, BNMS Clinical Practitioners’ Group.
Phil Facey, AshbyGB, Past-Chair, BNMS Clinical Practitioners’ Group.
15.36-15.48  Technical Errors Associated with Incorrect Renogram Processing and How to Avoid these.
P Josephs, J Mateo-Vito, S Navalkissoor, Royal Free London NHS Foundation Trust, London, UK
15.48-16.00  Nuclear Medicine Technologists Education and Training in Europe
A. Matos, R. Massa, T. Vaz, F. Lucena, Escola Superior de Tecnologias da Saude de Lisboa, Lisbon, Portugal
16.00-16.20  Tea & Coffee in the Exhibition Hall
16.20-18.00  CLINICAL PRACTITIONERS: PROFFERED PAPERS
Chairs Sandra Johns & Lloyd Rowling
16.20-16.32  Simultaneous PET-MRI: Challenges for Technologists and Radiographers
J Stirling, J John, L Shalaby, V Goh, GI Cook, P Patel, Kings College London, London, UK
16.32-16.44  Usefulness of Non-Attenuation Correction Images In Suspected Cardiac Implantable Electronic Device Related Infection
C. Abreu', J. O’Doherty', A. Corrigan', S. Barrington', J. John', A. Jacob', S. Pereira', L. Alves', R. Cabral', PET Imaging Centre, Division of Imaging Sciences and Biomedical Engineering, King’s College London, King’s Health Partners, St Thomas’ Hospital, London, UK, ‘Department of Radiology, Maidstone Hospital, Maidstone and Tunbridge Wells NHS Trust, Kent, UK
16.44-16.56  Are Radiation Protection Restrictions Required For Patients Following 64 Cu-ATSM PET Studies?
S. Pereira, E. Woods, J. John, A. Jacob, C. Abreu, L. Alves, R. Cabral, Y. Suh, L. Pike PET Imaging Centre, St Thomas’ Hospital, Division of Imaging Sciences and Biomedical Engineering, King’s College London, King’s Health Partners, London, UK
16.56-17.08  Is A ‘Blunted’ Heart Rate Response (HRR%) to Regadenoson Stress An Adverse Prognostic Indicator For Future Cardiac Events In Patients With A ‘Low Risk’ Myocardial Perfusion Study (MPS)?
AS Reimao, N Singh, M Aplin, A Clarke, A Hosur, K Day, S Dizdarevic, Brighton and Sussex University Hospitals NHS Trust, Brighton, Sussex, UK

17.08-17.20  The Influence of Quantification on SPECT 123Ioflupane Reporting
A Matos, M Jessop, AM Peters, N Singh, A Hosur, V Raman, G Keramida, M Aplin, S Dizdarevic, Nuclear Medicine, Department of Imaging, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK
17.20-17.32  Validation of A Personal Electronic Dosimeter and Its Use In Assessing How Individual Tasks Contribute to Overall Staff Dose During 18FDG PET Scanning; How Low Can It Go?
C Renshaw, G Pawson, J Mbutu-Austin, S Bartley, A Bradley, Central Manchester University Hospitals, Manchester, UK
17.32-17.44  Analysis of Methods for Technologist Dose Reduction in a PET-CT Department
L Alves, J Joemon, A Jacob, S Pereira, R Cabral, E Woods, PET Imaging Centre, Division of Imaging Sciences & Biomedical Engineering, King’s College London, King’s Health Partners, St. Thomas’ Hospital, London, UK
17.44-17.56  Operational Changes to Accommodate SPECT-CT Bone Studies
J Thompson-Peters, D Dawkins, J O’Brien, N Smith, W Thomson, A Jefferies, City Hospital, Birmingham, UK
17.56-18.08  Imaging Time and Collimator Choice when OSEM with Resolution Modelling Is Used For Myocardial Perfusion SPECT Reconstruction - A Phantom Study
A List, Imperial College Healthcare NHS Trust, London, UK

18.15-19.45 PRESIDENT’S RECEPTION - EXHIBITION HALL

MEETING ROOM 5
14.00-14.45  MEDICS FORUM - DISCUSS ‘HOT TOPICS’
Chair Dr Sabina Dizdarevic
1. New Services: Impact on patients’ management
Prof Gary Cook King’s College London
2. Workforce - Update
3. New curriculum/training: Information for clinical and educational supervisors
4. PET-CT national contract
5. Radiopharmaceuticals: production and supply
### AUDITORIUM 2

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30-10.30</td>
<td><strong>MASTERCLASS IV: LUNG CANCER</strong></td>
<td>Dr Brent Drake &amp; Dr Richard Graham</td>
</tr>
<tr>
<td>08.30-09.00</td>
<td><em>Aetiology, pathogenesis and diagnosis of Lung cancer</em></td>
<td>Dr Vineet Prakash St Peter’s Hospital Surrey</td>
</tr>
<tr>
<td>09.00-09.30</td>
<td><em>Current Status of Management of lung cancer: Focus on Surgical Perspective</em></td>
<td>Mr David Lawrence University College London Hospitals NHS Foundation Trust</td>
</tr>
<tr>
<td>09.30-10.00</td>
<td><em>PET in lung cancer: New Changes in Practice and Challenges</em></td>
<td>Dr Prakash Manoharan The Christie NHS Foundation Trust</td>
</tr>
<tr>
<td>10.00-10.30</td>
<td>Questions and Answers</td>
<td>Dr Brent Drake, Plymouth Hospitals NHS Trust</td>
</tr>
<tr>
<td>10.30-11.00</td>
<td>Tea &amp; Coffee in the Exhibition Hall</td>
<td></td>
</tr>
<tr>
<td>11.00-13.00</td>
<td><strong>MASTERCLASS V: LYMPHOMA</strong></td>
<td>Dr Francis Sundram &amp; Dr Lorenzo Biassoni</td>
</tr>
<tr>
<td>11.00-11.30</td>
<td><em>Aetiology, pathogenesis and diagnosis of Lymphoma:</em></td>
<td>Dr Irfan Kayani Institute of Nuclear Medicine, UCLH</td>
</tr>
<tr>
<td>11.30-12.00</td>
<td><em>Current Status of Management of Lymphoma</em></td>
<td>Dr Jonathan Lambert University College London Hospitals NHS Foundation Trust</td>
</tr>
<tr>
<td>12.00-12.30</td>
<td><em>PET/CT in Lymphoma: Focus on Recent Change in Guidelines</em></td>
<td>Dr Sally Barrington PET Centre at St Thomas’, King’s College London</td>
</tr>
<tr>
<td>12.30-13.00</td>
<td>Questions and Answers</td>
<td>Dr Francis Sundram University Hospital Southampton</td>
</tr>
<tr>
<td>13.00-14.00</td>
<td>Lunch &amp; Meet Industry in the Exhibition Hall</td>
<td></td>
</tr>
<tr>
<td>13.15-13.45</td>
<td>Moderated Poster Session</td>
<td></td>
</tr>
<tr>
<td>14.00-15.00</td>
<td><strong>ANNUAL LECTURE</strong></td>
<td>Chairs Dr Alp Notghi &amp; Dr Gopinath Gnanasegaran</td>
</tr>
<tr>
<td></td>
<td><em>THE EVOLVING ROLE OF CLINICAL MOLECULAR IMAGING IN MULTI-DISCIPLINARY CANCER CARE</em>:</td>
<td>Professor Homer Macapinlac, MD Anderson Cancer Centre, The University of Texas</td>
</tr>
<tr>
<td>15.00-15.10</td>
<td>WHAT IF YOU COULD SEE PEOPLE’S THOUGHTS, FEELINGS?:</td>
<td>Dr Alp Notghi</td>
</tr>
<tr>
<td></td>
<td>EMPATHY: EXPLORING HUMAN CONNECTION (VIDEO 1)</td>
<td>COURTESY: CLEVELAND CLINIC, USA</td>
</tr>
</tbody>
</table>

### SYNDICATE 2

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Chair or Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30-10.30</td>
<td><strong>RADIOPHARMACY: MOLYBDENUM SUPPLY 2016 -2022</strong></td>
<td>Chairs J Croasdale &amp; Dr B Ellis</td>
</tr>
<tr>
<td>08.30-08.45</td>
<td>Overview of Mo-99 Global Supply</td>
<td>Dr B Neilly, Glasgow Royal Infirmary</td>
</tr>
<tr>
<td>08.45-09.00</td>
<td>Options for Tc-99m production in the UK</td>
<td>Prof A Perkins. Nottingham University Hospitals NHS Trust, Nottingham</td>
</tr>
<tr>
<td>09.00-09.15</td>
<td>The Canadian Tc-99m products: Synthesis and specifications</td>
<td>Dr B Ellis Central Manchester University Hospitals NHS Foundation Trust</td>
</tr>
<tr>
<td>09.15-09.30</td>
<td>Regulatory Issues affecting the cyclotron production of Tc-99m</td>
<td>Dr J Ballinger Guy’s and St Thomas’ NHS Foundation Trust</td>
</tr>
<tr>
<td>09.30-09.45</td>
<td>How will you manage Molybdenum shortage from 2016 - 2022?</td>
<td>GE Response, Julie Woodland, GE Healthcare Ltd</td>
</tr>
<tr>
<td>09.45-10.00</td>
<td>Alliance/ IBA Response:</td>
<td>Howard Marsh, Chief Financial Officer, Allinace Medical UK and Northern Europe</td>
</tr>
<tr>
<td>10.00-10.15</td>
<td>Mallinckrodt Response:</td>
<td>Roy Brown Senior Director of Strategic Alliances</td>
</tr>
<tr>
<td>10.15- 10.30</td>
<td>Panel discussion</td>
<td></td>
</tr>
<tr>
<td>10.30-11.00</td>
<td>Tea &amp; Coffee in the Exhibition Hall</td>
<td></td>
</tr>
<tr>
<td>11.00-13.00</td>
<td><strong>RADIOPHARMACY: PROFERRED PAPERS</strong></td>
<td>Chairs J Croasdale, Dr B Ellis</td>
</tr>
</tbody>
</table>

---

**FULL PROGRAMME TUESDAY 28TH APRIL**

---

**WHAT IF YOU COULD SEE PEOPLE’S THOUGHTS, FEELINGS?:**

**EMPATHY: EXPLORING HUMAN CONNECTION (VIDEO 2)**

**COURTESY: CLEVELAND CLINIC, USA**

**GA-68-PSMA PET/CT IMAGING: THE GAME CHANGER,**

Dr Kumar Kallur Healthcare Global Enterprises Ltd, Bangalore, Karnataka, India

**Tea & Coffee in the Exhibition Hall**

**BNMS ANNUAL GENERAL MEETING**
11.00-11.12  60. Validation of Extended Expiry of 99mTc Labelled Radiopharmaceuticals
VJ Gibson1, A Al-Mossawi1, JR Ballinger1,2, ‘Guy’s and St Thomas’ Hospital, London, UK, 2King’s College London, London, UK

11.12-11.24  61. Optimization of Cyclotron Production of Zirconium 89
A M Dabkowski, C Marshall, Cardiff University, Cardiff, UK

11.24-11.36  62. Rapid 68Ga-Radiolabelling of Proteins In Mild Conditions
Exploiting A Novel Tris(Hydroxypyridinone) Bifunctional Chelator
C Imberti, M.T Ma, PJ Blower, King’s College London, London, UK

11.36-11.48  63. One-Step, Mild Efficient 68Ga “Cold” PET Kits: Performance
Characteristics and Robustness of Tris(Hydroxypyridinone) Chelators.
J Young1, M Cooper1, B Paterson1, M Ma1, J Ballinger1, S Nawaz2, D Berry1, R Hider2, G Mullen1, P Blower1, ‘King’s College London, Division of Imaging Sciences and Biomedical Engineering, London, UK, 2King’s College London, Institute of Pharmaceutical Science, London, UK

11.48-12.00  64. A Nationwide Audit On Solid Gastric Emptying:
Assessing Disparity Amongst The Departments
S Hansrod, A Notghi, J Croasdale, Sandwell and west Birmingham Hospital NHS Trust, Birmingham, UK

12.00-12.12  65. Impact of Changes to Cell Labelling Technique On The Results of
Indium-Labelled Platelet Imaging For ITP Patients
F McKiddie1, J Phillips1, D Graham2, H Watson1, RT Staff1, 1Nuclear Medicine Department, NHS Grampian, Aberdeen, UK, 2Pharmacy Department, NHS Grampian, Aberdeen, UK

12.12-13.00 Radiopharmaceutical Sciences Group AGM

13.00-14.00 Lunch & Meet Industry in the Exhibition Hall

13.15-13.45 Moderated Poster session

14.00-15.00 ANNUAL LECTURE
"THE EVOLVING ROLE OF CLINICAL MOLECULAR IMAGING IN MULTI-DISCIPLINARY CANCER CARE":
Professor Homer Macapinlac, MD Anderson Cancer Centre, The University of Texas

15.45-16.15 TRAINEES FORUM
Deena Neriman

16.15-16.30 Tea & Coffee in Exhibition Hall

SYNDICATE 3

08.30-10.30 INVITED REVIEW & PROFFERED PAPERS
Chairs Dr Robert Reid & Dr Paul Ryan

08.30-09.00 The cost of Nuc Med: HRG codes and Tariffs.
Nathan Abbotts Health and Social Care Information Centre

09.00-09.20 The cost of Nuc Med: HRG codes and Tariffs.
Sarah Allen Guy’s and St Thomas’ NHS Foundation Trust

09.20-09.40 The cost of Nuc Med: HRG codes and Tariffs.
Dr Margaret Hall Royal Free London NHS Foundation Trust

09.40-10.10 Trials and Tribulations of a mobile PET/CT service.
Dr Claire Beadsmoore Norfolk and Norwich University NHS Foundation Trust

10.35-11.00 Tea & Coffee in the Exhibition Hall

11.00-13.00 NEUROLOGY: INVITED REVIEW & PROFERRED PAPERS
Chairs Dr Vikram Lele & Dr Simon Hughes

11.00-11.30 Who should be considered for an amyloid scan?
Experiences from a dementia MDT
Dr Richard Perry, Consultant Neurologist, Imperial College Healthcare NHS Trust, London
Eli Lilly and Company LTD have sponsored the content of this session

11.30-11.42 49. The Effect of Various Types and Severity of Motion on Datscan Images and Quantification using a Novel Method
G James, A Notghi, City Hospital, Birmingham, UK

11.42-11.54 50. Assessing the Diagnostic Impact of FDG-PET-CT Imaging on Final Diagnosis in Patients with Mild Cognitive Impairment
K Day1, A Hosur1, G Raczek1, B H Ridha1, A H Mahdi1, S Dizdarevic1, 1Brighton and Sussex University Hospitals Trust, Brighton, East Sussex, UK, 2University of Sharjah, Khor Fakkan, United Arab Emirates, 3Sussex Partnership NHS Foundation Trust, Worthing, East Sussex, UK
### Tuesday

**11.54-12.06** 51. Initial Experience of The Utility of An Automated Quantitative Cortex Mapping Software For FDG PET-CT Assessment of Cerebral Metabolism.

J Cain, J Hill, Lancashire Teaching Hospitals NHS Trust, Preston, Lancashire, UK  
★ Joint 2nd Place Student Prize ★

**12.06-12.18** 52. Amyvid® Scan Time: How Low Can You Go?

AJ Cole1, L Perry1, B Williams2, W Svensson1, KS Nijari1, Z Win2, 1Radiological Sciences Unit, Imperial College Healthcare NHS Trust, London, UK, 2Nuclear Medicine Department, Imperial College Healthcare NHS Trust, London, UK

**12.18-12.30** 53. Prognostic Value of 18F-Florbetapir Scan: A 36-Month Follow Up Analysis Using ADNI Data

M Lu1, M Pontecovro1, A Siderovfi1, AD Joshi1, M Devous1, M Mintun1, A Lenox-Smith2  
1Avid Radiopharmaceuticals, Inc, Philadelphia, PA, USA, 2Lilly UK, Lilly House, Basingstoke, Hampshire, UK

**12.30-12.42** 54. Potential Effect of Amyloid Imaging on Diagnosis and Intended Management of Patients with Cognitive Decline: Impact of Appropriate Use Criteria.

G Dell’Agnello1, M Pontecovro1, M Lu1, C Hunter1, AK Arora1, M Mintun1, A Lenox-Smith2, 1Eli Lilly and Company or a wholly owned subsidiary, Indianapolis, IN, USA, 2Lilly UK, Lilly House, Basingstoke, Hampshire, UK

**12.42-12.54** 55. A Comparison of the Psychological Burden Caused by PET-MRI and PET-CT scans

R Shortman1,2, D Neriman1,2, J Hoath1,2, L Millner1,2, R Endoza2, G Azzopard1,2, 1University College London, London, UK, 2University College Hospital, London, UK

**13.00-14.00** Lunch & Meet Industry in the Exhibition Hall

**13.15-13.45** Moderated Poster Session

**14.00-15.00** ANNUAL LECTURE

*THE EVOLVING ROLE OF CLINICAL MOLECULAR IMAGING IN MULTI-DISCIPLINARY CANCER CARE*:

Professor Homer Macapinlac, MD Anderson Cancer Centre, The University of Texas

**16.00-16.30** Tea & Coffee in Exhibition Hall

**16.30-18.00** NUCLEAR MEDICINE: MISCELLANEOUS PROFFERED PAPERS

Chair Dr Jackie James

Parathyroid Imaging: Overview

Dr Vineet Prakash, Ashford and St. Peter’s Hospitals NHS Foundation Trust

**17.00-17.12** 56. Planar and SPECT Ventilation/Perfusion Imaging and Computed tomography Pulmonary Angiography For The Diagnosis of Pulmonary Embolism: A Systematic Review, Meta-Analysis of The Literature, Cost Effectiveness Analysis, and Dose Comparison.

JJ Phillips, RA Staff, J Straiton, Grampian NHS, Aberdeen, UK

**17.12-17.24** 57. Lobar Quantification of Lung Perfusion and Ventilation: A Comparison of Two Different Processing Methods Using SPECT VQ/CT

CD Baker, S Gregg, J Bailey, JC Fowler, SR Underwood, K Wechalekar, Royal Brompton & Harefield NHS Foundation Trust, London, UK

**17.24-17.36** 58. Gastric Emptying Scintigraphy In Paediatric Gastroparesis; Are we Using The Correct Normal Ranges?

S Mohammadi, B kearl, H Banoub, S Chong, A Parthipun, St Helier Hospital, London, UK

**17.36-17.48** 59. Our Experience with the SNM Gastric Emptying Protocol

N Vennart1,2, G Roberts2, J Atkinson1, D Limmer1, I Wells1, Y Yiannikou3, E Jefferson2  
1Regional Medical Physics Dept. North Tees and Hartlepool Foundation Trust Unit, Hartlepool, UK, 2Regional Medical Physics Dept. County Durham and Darlington Foundation Trust Unit, Durham, UK, 3County Durham and Darlington Foundation Trust, Durham, UK

**08.30 - 10.30** CLINICAL PRACTITIONERS: CONTINUING EDUCATION SERIES 3

Chairs S Johns & P Delf

08.30-09.00 Nuclear Medicine and Therapy.

Dr Shaunak Navalkissor Royal Free London NHS Foundation Trust

09.00-09.30 Nuclear Medicine and Therapy: Role of technologists

Ivy Vito, Royal Free London NHS Foundation Trust

09.30-10.00 Radiation Safety in Radionuclide therapy

Dr Jeff Jones, The Royal Free London NHS Foundation Trust

10.00-10.30 PET/CT: Delivering high quality service: A technologists perspective

Dr Joeman John, Clinical PET centre, Guys & St Thomas NHS Hospital

**10.30-11.00** Tea & Coffee in the Exhibition Hall

**11.00-13.00** CLINICAL PRACTITIONERS CONTINUING EDUCATION SERIES 4

Chairs L Rowling and N Gulliver

11.00-11.30 Nuclear Medicine and Paediatric brain imaging

Dr Lorenzo Biassoni Great Ormond Street Hospital for Children NHS Foundation Trust

11.30-12.00 Gated blood pool imaging: Technical challenges and solutions

Dr Parthiban Arumugam Central Manchester University Hospitals
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.00-12.30</td>
<td>CT Workshop for Nuclear Medicine Technologists – Part 2 (abdomen &amp; pelvis)</td>
<td>Dr Vineet Prakash Ashford and St. Peter's Hospitals NHS Foundation Trust</td>
</tr>
<tr>
<td>12.30-13.00</td>
<td>Read with the Experts (Clinical): Interactive Clinical Quiz</td>
<td>Dr Parthiban Arumugam Central Manchester University Hospitals - NHS Foundation Trust and Dr Brent Drake Plymouth Hospitals NHS Trust</td>
</tr>
<tr>
<td>13.00-14.00</td>
<td>Lunch &amp; Meet Industry in the Exhibition Hall</td>
<td></td>
</tr>
<tr>
<td>13.15-13.45</td>
<td>Moderated Poster Session</td>
<td></td>
</tr>
<tr>
<td>14.00-15.00</td>
<td>ANNUAL LECTURE</td>
<td>“THE EVOLVING ROLE OF CLINICAL MOLECULAR IMAGING IN MULTI-DISCIPLINARY CANCER CARE”:</td>
</tr>
<tr>
<td></td>
<td>Professor Homer Macapinlac, MD Anderson Cancer Centre, The University of Texas</td>
<td></td>
</tr>
<tr>
<td>16.00-16.30</td>
<td>Tea &amp; Coffee in Exhibition Hall</td>
<td></td>
</tr>
<tr>
<td>16.30-18.00</td>
<td>PET/CT CASE REVIEW: “DEALING WITH THE CLINICAL CHAMELEON”</td>
<td>Moderators Dr Teresa Szyszko &amp; Dr Irfan Kayani</td>
</tr>
<tr>
<td>16.30-17.15</td>
<td>Interesting PET/CT Cases (Brain, head &amp; Neck, lung, Miscellaneous)</td>
<td>Dr Teresa Szyszko PET Imaging Centre at St Thomas’, Dr Simon Wan</td>
</tr>
<tr>
<td>17.15-18.00</td>
<td>Interesting PET/CT Cases (Lymphoma, CRC, NET, Miscellaneous)</td>
<td>Dr Irfan Kayani Institute of Nuclear Medicine, UCLH</td>
</tr>
</tbody>
</table>
FULL PROGRAMME WEDNESDAY 29TH APRIL

AUDITORIUM 2

09.00-10.30 YOUNG INVESTIGATORS PRIZE
- Chairs Dr Francis Sundram & Prof S Vinjamuri

08.30-08.50 66. Negative ¹⁸⁸F-FDG-PET-CT May Exclude Residual Or Recurrent Disease In Anal Cancer
- A Teagle1, D Gilbert1, J Jones2, G Burkill2, F McInnna3, S Dizdarevic1, 'Brighton and Sussex University Hospitals NHS Trust, Brighton, UK, 'King’s college Hospital NHS Foundation Trust, London, UK

08.50-09.10 67. ⁶⁷Ga DOTATATE PET-CT: What Is The Minimum Activity Necessary to Maintain Lesion Detectability In The Liver?

09.10-09.30 68. Improving SUV Normalisation for ¹⁸⁸F-FDG PET-CT using CT Fat Segmentation.
- G Woolley, M Burniston, H McMeekin, F Wickham, T Wagner, D McCool, Royal Free Hospital, London, UK

09.30-09.50 69. Ventilation/Perfusion (V/Q) Scintigraphy with SPECT and SPECT-CT: Moving From Probability to Holistic Reporting.
- C Sit1, R Mandegaran2, C Sibley-Allen3, D Dasgupta4, G Gnanasegaran5, 'King’s College London, London, UK, 'Department of Radiology, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, 'Department of Nuclear Medicine, Guy’s and St Thomas’ NHS Foundation Trust, London, UK

10.00-10.30 REPORT ON TRAVELLING FELLOWSHIP REPORT 2015
- Dr Michael Kay, University Hospital Southampton, Travelling Fellowship Award Winner 2015

10.30-10.45 Tea & Coffee in the Exhibition Hall

10.45-12.15 NUCLEAR MEDICINE: MISCELLANEOUS
- Chairs Dr Richard Graham & Sarah Allen

10.45-11.15 Setting up Alpharadin Therapy Service
- Dr Francis Sundram University Hospital Southampton

11.15-11.45 Infection Imaging in Orthopaedics,
- Prof Sobhan Vinjamuri Royal Liverpool University Hospital

11.45-12.15 Movers and Shakers in Endocrinology
- Dr Rakesh Sajjan University College London Hospitals NHS Foundation Trust

12.15-12.30 AWARDS CEREMONY
- Chairs Dr Alp Notghi

12.30-13.15 HIGHLIGHTS LECTURE DR BRIAN NEILLY
- Chairs Dr Alp Notghi

13.15-14.00 Lunch and Close of Meeting

SYNDICATE 3

08.30-10.30 RADIONUCLIDE RADIOTHERAPY PROFERRED PAPERS
- Chair Dr Shaunak Navalkissor

08.30-08.42 70. Establishing A Nuclear Medicine Led Radium-223 (Ra-223) Radionuclide Therapy Service: South of England Single Centre Experience
- M Kay, R Kulanthaivelu, S Johns, J Harris, S Greenslade, C Zvavamwe, S Rhodes, M Guy, F Sundram, University Hospital, Southampton, UK

08.42-08.54 71. Radium- 223 Radionuclide Therapy For Patients With Symptomatic Bony Metastatic Castration Resistant Prostate Cancer (mCRPC): Initial Clinical Experience from University Hospital Southampton (UHS)
- R Kulanthaivelu, M Kay, S Johns, F Sundram, University Hospital, Southampton, UK

08.54-09.06 72. Can Low Dose Radioiodine Thyroid Ablation Be Performed As A Day Case? A Retrospective Study Into Activity Retention Times

09.06-09.18 73. A Software Phantom for Testing Dosimetric Calculations For Multi-Centre Studies - Application to ¹⁷⁷Lu-DOTATATE and The UK Internal Dosimetry Users Group
- L Livieratos1, M Aldridge2, M Guy3, E Kalogianni4, DR McGowan5, B Rojas6, J Tipping7
- 1Guy’s and St Thomas’ NHS Foundation Trust, London, UK, 2University College London Hospitals NHS Foundation Trust, London, UK, 3‘University Hospital Southampton NHS Foundation Trust, Southampton, UK, 4‘King’s College Hospital NHS Foundation Trust, London, UK, 5‘Oxford University Hospitals NHS Trust, Oxford, UK, 6‘Royal Brompton & Harefield NHS Foundation Trust, London, UK, 7‘Christie NHS Foundation Trust, Manchester, UK
09.18-09.30 74. Radiation Protection Considerations For 177Lutetium- Dotatate PRRT: From Delivery to Discharge.

09.30-09.42 75. Breast Dose From Lactation Following 131I Treatment
WH Thomson1, C Lewis2, 1City Hospital, Physics and Nuclear Medicine, Birmingham, UK, 2City Hospital, Maternity, Birmingham, UK

09.42-09.54 76. Dosimetry and Survival in Patients with Bone Metastases from Prostate Cancer Treated with 186Re-HEDP
A M Denis-Bacela1, A Divoli1, S Chittenden1, D P Dearnaley1, J M O’Sullivan1, Y Du2, K J Frisch1, G D Flux2, 1Institute of Cancer Research, London, UK, 2Royal Marsden Hospital, London, UK, 3Queen’s University Belfast / Northern Ireland Cancer Centre, Belfast, UK

09.54-10.06 77. QUALITY OF LIFE: Patient Response after 1st Treatment (PRRT)
I Mateo-Vito, R Leshen, H McMeekin, S Navalkissoor, Royal Free London NHS Foundation Trust, London, UK

10.06-10.18 78. A Survey of Patient Restrictions For 131I Thyrotoxicosis Treatment; Calculated Doses and Their Implications.
WH Thomson, City Hospital, Birmingham, UK

10.18-10.30 79. 223Ra-Dichloride Treatment In Clinical Practice: Extent of Bone Disease and Alkaline Phosphatase (ALP) Response Vs. Outcomes
S Dizdarevic, M Jessop, M Aplin, N Singh, A Hosur, K Day, A Nikapota, F McKinna, A Robinson, Royal Sussex County Hospital, Brighton, UK

10.30-10.45 Tea & Coffee in the Exhibition Hall

12.15-12.30 AWARDS CEREMONY

12.30-13.15 HIGHLIGHTS LECTURE DR BRIAN NEILLY
Chairs Dr Alp Notghi

13.15-14.00 Lunch and Close of Meeting

SYNDICATE 4

08.30-10.30 NUCLEAR MEDICINE: MISCELLANEOUS PROFERRED PAPERS 2
Chair Prof Drazen Huic & Prof Jasna Mihailovic

08.30-08.42 80. PET Imaging of Changes in Copper Metabolism Associated With Alzheimer’s Disease: Potential New Diagnostics
J Baguña torres, E andreozzi, A Gee, P Blower, King’s College London, London, UK

08.42-08.54 81. ROC Comparison of Scintigraphic Parathyroid Localisation Techniques.
KC Cockburn1, N Ahmed2, GR Avery2, GA Wright1, 1Department of Nuclear Medicine, Castle Hill Hospital, Cottingham, East Riding of Yorkshire, UK, 2Department of Radiology, Castle Hill Hospital, Cottingham, East Riding of Yorkshire, UK

08.54-09.06 82. Iodine-125 Seeds in the Localisation of Breast Tumours: A UK First!
R Peace, N Khonji, The Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne, UK

09.06-09.18 83. Quantification of The Activity of Tritium Produced During The Routine Synthesis of 18F Fluorodeoxyglucose For Positron Emission tomography
MA Talboys1,2, C Marshall1, S Bukhari1, WD Evans1,2, 1Wales Research and Diagnostic Positron Emission tomography Imaging Centre (PETIC), School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, Wales, UK, Cardiff, UK, 2Medical Physics and Clinical Engineering, Cardiff and Vale University Health Board, University Hospital of Wales, Heath Park, Cardiff CF14 4XW, Wales, UK, Cardiff, UK, 3Institute of Medical Engineering and Medical Physics, School of Engineering, Cardiff University, Queen’s Building, The Parade, Cardiff CF24 3AA, Wales, UK, Cardiff, UK

09.18-09.30 84. Local Diagnostic Performance Using Serial Brain Imaging With 99mTc-HMPAO and 123I-FP-CIT (DaTSCAN) In The Evaluation of Patients With Dementia When Differentiating Alzheimer’s Disease From Lewy Body Dementia.
R Brown, PS Chuah, R Berhane Menghis, S Vinjamuri, Royal Liverpool University Hospital, Liverpool, UK

09.30-09.42 85. Quantitative Analysis of FDG PET and MPS Images For Diagnosis and Follow Up In Cardiac Sarcoiodosis
B Rojas, L Hossen, S Gregg, V Kouranos, K wechalekar, Royal Brompton Hospital, London, UK

09.42-09.54 86. Sensitivity of QC Methods For Slope-Intercept GFR Calculation
H McMeekin1, F Wickham1, M Barnfield2, M Burniston1, 1Royal Free London NHS Foundation Trust, London, UK, 2St James’s University Hospital, Leeds, UK

09.42-09.54 87. Identification of The Most Accurate Single-Sample Technique For Measurement of Glomerular Filtration Rate (GFR) For All Ages
H McMeekin, M Burniston, F Wickham, M Barnfield, Royal Free London NHS Foundation Trust, London, UK
P1  Follow-up studies of 18F sodium fluoride PET/CT bone studies in patients with breast cancer. Planar bone scintigraphy versus 18F sodium fluoride PET/CT: which are we doing and why?  
R.K. Kulshresthaa,b, S. Vinjamurib,c, P. Hoggc and A. Englandc  
aCentral Manchester University Teaching Hospitals NHS Foundation Trust, Manchester,  
bRoyal Liverpool University Teaching Hospitals NHS Foundation Trust, Liverpool and cUniversity of Salford, Salford, UK

P2  How useful are our SPECT/CT bone scans?  
Sandwell & West Birmingham Hospitals NHS Trust, West Midlands, UK

P3  Initial assessment of xSPECT quant for SPECT/CT bone scanning  
V. Rowse, L. Vass and A.G. Irwin  
St. George's Hospital, London, UK

P4  Dose adjustment for bone studies on obese patients: where’s the evidence?  
F.H. Barracka,b, G. Bolognab, M. Brancob, O. Ghafoorb, M. Brancob, O. Ghafoorb, P.J. Hintona, V. Prakashb, J.Q. Scuffhama and J.J. Simpsonb  
aRoyal Surrey County Hospital, Guildford, Surrey and aRoyal Surrey County Hospital, Guildford, Surrey, UK

P5  SPECT-CT imaging in osteoporosis related back pain  
Paul Ryan  
Medway Maritime Hospital, Gillingham, UK

P6  P6 Detection of diastolic ventricular interaction in chronic heart failure from MUGA scans  
F.I. McKiddiea, S. Singhb and R.T. Staffa  
aNuclear Medicine Department, NHS Grampian and bCardiology Department, NHS Grampian, Aberdeen, UK

P7  The impact of computed tomography cardiac angiography (CTCA) on the myocardial perfusion scintigraphy (MPS) service: a retrospective service evaluation study  
H.G. Whiteley-Jones, J. Deane, S. Dizdarevic and V. Raman  
Brighton and Sussex University Hospitals NHS Trust, Brighton, UK

P8  Assessment of the variability of left ventricular ejection fraction (LVEF) between software algorithms in radionuclide ventriculography (RNVG)  
aGlasgow Royal Infirmary, Glasgow, bAiglemore Hospital, Inverness, UK and cAberdeen Royal Infirmary, Aberdeen, UK

P9  Phase analysis of radionuclide ventriculography: assessment of herceptin cardiotoxicity  
A. Al-Jabrib, C. Patersona,b, J. Robinsona, W. Martinb, S. Reida and S. Smithb  
aNuclear Cardiology, Glasgow Royal Infirmary, Glasgow and bSchool of Medicine, Glasgow University, Glasgow, UK

P10  Value of CT in MPI: attenuation correction and coronary calcium assessment  
N. Bebbington, Y. Wahid, B. Holloway and R. Steeds  
Queen Elizabeth Hospital Birmingham, Birmingham, UK

P11  A negative stress only myocardial perfusion provides excellent prognostic accuracy  
D.S. Bulugahapitiya, A. Feben, M.P. Avison, J. Foley and J. Martin  
Bradford Teaching Hospitals NHS Trust, Bradford, UK

P12  Papillary thyroid cancer with pleural metastases  
J. Siddiquia, S. Saccaramb, E. Nowosinskaa, W. Drakea and H. Janb  
aDepartment of Radiology, St Bartholomew’s Hospital, bDepartment of Nuclear Medicine, London, UK and cDepartment of Endocrinology, London, UK

P13  The role of functional and radiology imaging in evaluation of metastatic parathyroid cancer  
C. Leunga, M. Newellb, E. Nowosinskaa, W. Drakea and H. Janb  
aRadiology Department, St. Bartholomew’s Hospital, bNuclear Medicine Department St. Bartholomew’s Hospital and cEndocrinology Department, St Bartholomew’s Hospital, London, UK

P14  Comparison of two doses of radio-iodine for the treatment of thyrotoxicosis and correlation with thyroid uptake imaging pre-treatment  
S. Savaridasa, G. Robertsb, E. Jeffersoa and K. Whickerb  
aNorth Tyneside General Hospital, Tyne-and-Wear, UK, bUniversity Hospital North Durham, Durham, UK and cHartlepool Memorial Hospital, Hartlepool, UK

P15  Audit of radioiodine therapy in benign thyroid disease at east kent university hospitals according to the royal college of physicians guidelines  
E. Nikolou and G. Shabo  
East Kent Hospitals University NHS Foundation Trust, Kent and Canterbury Hospital, Ethelbert Road, Canterbury, Kent, UK
P16 Exploring possible causes of venous uptake of $^{99m}$Tc MIBI
   A. Smout, J. Hall, A. Fullbrook, J. Ward and L. Wright
   Frimley Park Hospital, Frimley, Surrey, UK

P17 Mucinous adenocarcinoma of unknown origin: an unusual thyroid presentation
   A. Hosur, A. Teagle, M. Koenig, A. Rainey, J. Simpson and S. Dizdarevic
   Brighton and Sussex University Hospitals NHS Trust, Brighton, UK

P18 Squamous cell carcinoma of the thyroid: case series and literature review
   A. Teagle, A. Hosur, C. Zammit, V. Raman, N. Singh and S. Dizdarevic
   Brighton and Sussex University Hospitals NHS Trust, Brighton, UK

P19 Review of parathyroid imaging at east kent university hospitals in 2006 and 2011 to evaluate the reproducibility of parathyroid imaging in correlation with surgery and histopathology results
   P. Rai, K. Bryce and G. Shabo
   Kent and Canterbury Hospital, East Kent Hospital Foundation Trust, Canterbury, Kent, UK

P20 SPECT Ventilation/Perfusion (V/Q) quotient: a complimentary tool to evaluate matched and mismatched defects?
   FR Green, FU Hassan, C Sibley-Allen and G Gnanesarani
   “Guy's and St Thomas’ Hospitals NHS Trust, London, UK” and “King’s College London, London, UK

P21 Ventilation-Perfusion single photon emission computed tomography (VQ SPECT) and computed tomography pulmonary angiography (CTPA) correlation in the detection of pulmonary embolism (PE)
   C. Low, J. Cullis, A. Jennings, N. Williams and O. Adesanya
   University Hospitals Coventry and Warwickshire NHS Trust, Coventry, West Midlands, UK

P22 Initial experience of DMSA SPECT-CT in the assessment of paediatric renal calculi
   F. Ashford, E. Joel, L. Biaisson, M. Easty and G. Heath
   “Great Ormond Street Hospital for Sick Children NHS Foundation Trust, London, UK” and “Barts Health NHS Trust, London, UK

P23 Bone scan with low-dose SPECT-CT in paediatric back pain: acquisition details, dosimetry, and image quality
   E. Ali, F. Hussain, E. Joel, L. Biaisson, M. Easty and R. Nadarajah
   “Great Ormond St Foundation Trust, London” and “Barts Health NHS Trust, London, UK

P24 ISAS accreditation: what does it mean to a nuclear medicine department?
   D. Gillett and H. Rose
   Addenbrookes Hospital, Cambridge, UK

P25 Technetium-99m-MIBI SPECT/CT In Hyperparathyroidism - Institutional Review
   M. Khalid Nawaz, S. Mufy, H. Bashir and A. Hassan
   Department of Nuclear Medicine Shaukat Khanum Memorial Cancer Hospital & Research Centre, Lahore, Pakistan

P26 Review of first 6 months usage of $^{18}$F florbetapir brain imaging
   P.S. Chuah, R. Brown and S. Vinjamuri
   Nuclear Medicine Department, Royal Liverpool University Hospital, Liverpool, UK

P27 Impact of child-friendly environment on reducing the need for sedation in imaging
   Shaukat Khanum Memorial Cancer Hospital & Research Centre, Lahore, Pakistan

P28 The initial experience of the added value of SPECTCT in a general hospital setting: a pictorial review
   E. Owens, D. Sallomi, J. Ewer and H. Anderson
   Eastbourne District General Hospital, Eastbourne, UK

P29 Reproducible Lymph-To-Blood transfer of $^{99m}$Tcnanocolloid in a patient with abnormal lymphatic function
   G. Keramida, M. Lee, N. Singh and A.M. Peters
   Department of Nuclear Medicine, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK

P30 A review of GFR clearance studies in an oncology population: evaluating the potential for chemotherapy over-prescription
   A. Baker and M. Richardson
   James Cook University Hospital, Middlesbrough, UK

P31 Local experience of using intravenous $^{99m}$Tc macroaggregated albumin in the diagnosis of hepatopulmonary syndrome
   R. Brown, P.S. Chuah, I. Hufton and S. Vinjamuri
   Royal Liverpool University Hospital, Liverpool, UK
P32 MIBI renal and hepatic SPECT rate constants and correlation with ABCB1 genotypes in patients receiving ciclosporin treatment
-Brighton & Sussex University Hospitals NHS Trust, Brighton, UK and -Guy’s and St Thomas’ Trust, London, UK

P33 Reducing non completed PET/CT scans - a potential quality improvement initiative
A. Nunes, G. Beynon and W.L. Wong
Paul Strickland Scanner Centre - Mount Vernon Hospital, Northwood, Middlesex, UK

P34 The HIDA scan: making a meal of it
Glasgow Royal Infirmary, Glasgow, UK

P35 Establishing local CT DRLs for SPECT/CT imaging
A. Paramithas and A.G. Irwin
St. George’s Hospital, London, UK

P36 A novel technique to investigate the effect of patient motion for DaTSCAN studies
G. James and A. Notghi
City Hospital, Birmingham, UK

P37 Utility of PET-CT in critical care patients - a case of encephalitis diagnosed on PET-CT performed in a ventilated patient
J. Cain and J. Hill
Lancashire Teaching Hospitals NHS Trust, Preston, Lancashire, UK

P38 The complementary role of 18F-FDG PET and MR in evaluating the Cortico-Ponto-Cerebellar regions: a case study
J. Siddiqui, C. Leung, Y. Bouchareb, J. Evanson, H. Jan and A. Haroon
Barts Health NHS Trust, London, UK

P39 Unusual findings of CADISIL like appearances in a patient with adenocarcinoma of lung: paraneoplastic versus vascular disease
Brighton and Sussex University Hospitals NHS Trust, Brighton, UK

P40 Influence of slice overlap on positron emission tomography image quality
C. McKeown, G. Gillen, M.F. Dempsey and C. Findlay
Gartnavel General Hospital, NHS Greater Glasgow and Clyde, Glasgow, UK

P41 Continuous bed motion PET: should we go with the flow?
G.A. Wrighta, E. Papadopoulosb, J. Reidb and G. Avery
- Hull and East Yorkshire Hospitals NHS Trust, Cottingham, UK and -Alliance Medical Ltd, Warwick, UK

P42 Evolving role of 18F-FDG PET/CT in the investigation of pyrexia of unknown origin
N.S.A. Rafar, P. Vas, N. Mulholland, G. Vivian, A. Eccles and N. Gulliver
King’s College Hospital NHS Trust, London, UK

P43 Unusual neuroendocrine tumour metastases detected on 68Ga-DOTA-Peptide PET scans
D. Pencharz, H. McMeekin and S. Navalkissoor
Royal Free London NHS Foundation Trust, London, UK

P44 Non-physiological, non-neuroendocrine tumour uptake in 68Ga-DOTA-peptide PET scans
D. Pencharz, H. McMeekin and S. Navalkissoor
Royal Free London NHS Foundation Trust, London, UK

P45 Retrospective study investigating the role of FDG-PET/CT for patients presenting with weight loss
C. Tang, H. McMeekin and T. Wagner
Royal Free Hospital, London, UK

P46 Implementation of 18F-FDOPA nucleophilic synthesis using the trasis allinone synthesiser at PETIC
Cardiff University-PETIC, Cardiff, UK

P47 Disappearing pancreas - a case of pancreatic cancer detected on 18F-choline PET-CT
G. Burkill, G. Keramida, A. Nikapota, D. Hawkes and S. Dizdarevic
Department of Imaging, Brighton Sussex University Hospitals NHS Trust, Brighton, UK

P48 FDG PET/CT in carcinoma of unknown primary
S. Shahipasand and S. Navalkissoor
Department of Nuclear Medicine, Royal Free London NHS Foundation Trust, London, UK

P49 The use of FDG PET/CT in suspected paraneoplastic neurological syndromes: the experience of a singlecentre institution
G. Buckley, H. McMeekin and T. Wagner
Royal Free London NHS Trust, Royal Free Hospital, Pond Street, London, UK
P50 18F-fluoromethylcholine (18F-FMC) prostate imaging: a case study
T. Letchford, A. Nunes, A. Gogbashian and W. Wong
Paul Strickland Scanner Centre, Middlesex, UK

P51 The added value of 68Ga PET compared to CT for diagnosis and management of neuroendocrine tumours
N. Kalsy, R. Fernando and S. Vinjamuri
Royal Liverpool Hospital, Liverpool, UK

P52 The prevalence and relevance of incidental pathology on routine FDG PET-CT
A. Kamil and R. Ganatra
Queen’s Medical Centre Nottingham, Nottingham, UK

P53 Results of a UK survey of PET technology and imaging protocols for 18FDG-PET in oncology
L.C. Pikea, H.A. Williamsb, H.A. Armstrongb and M. Burnistonc
aPET Imaging Centre, St Thomas’ Hospital, Division of Imaging Sciences and Biomedical Engineering, King’s College London, King’s Health Partners, London, UK, bNuclear Medicine Centre, Central Manchester University Hospitals, Manchester, UK and cNuclear Medicine Department, Royal Free London NHS Foundation Trust, London, UK

P54 Quantitative 11C methionine PET/CT imaging in evaluation of bone lesions in cancer patients
SH Helmya, K Tanimotob and H Tsujib
aSouth Egypt Cancer Institute, Assiut University, Assiut, Egypt and bNational Institute of Radiological Sciences, Chiba, Japan

P55 An objective measurement of PET to CT alignment using the NEMA IQ phantom
D. Sinclair
King’s College London, London, UK

P56 Survival outcome after detection of colorectal recurrence on 18F FDG PET-CT: 2-year follow-up
H. Ahmeda, M.K. Nawaza, H. Bashira and S.A. Kazmi
aGuy’s and St Thomas’ Hospital, London, UK and bShaukat Khanum Memorial Cancer Hospital & Research Centre, Lahore, Pakistan

P57 Evaluation of Q.freeze software for PET respiratory gating of 18F-FDG PET-CT patients with liver lesions
D. Ruiz, N. Mulholland, A. Almeida, B. Corcoran, A. Eccles and G Vivian
King’s College Hospital NHS Foundation Trust, London, UK

P58 Comparison of PET reconstructions from two manufacturers with point spread function modelling and time-of-flight
I.S. Armstronga, K.E. Kennyb, L. Rowleyb and D.R. McGowan
aCentral Manchester University Hospitals, Manchester and bOxford University Hospitals, Oxford, UK

P59 Bowel malignancy in FDG PET-CT – a pictorial review
A. Kamil and R. Ganatra
Queen’s Medical Centre Nottingham, Nottingham, UK

P60 A pictorial atlas of 18F-FDG PET/CT staging in oesophageal cancer
C. Sita, F.R. Greena, G. Gnangesaranb and T.A. Szyszko
aKing’s College London and bGuy’s and St Thomas’ Hospitals NHS Trust, London, UK

P61 Pictorial atlas of 18F-FDG PET/CT staging in lung cancer
C Sita, F Green, G Gnangesaran and T Szyszko
aKing’s College London and bDepartment of Nuclear Medicine & PET/CT, Guy’s and St Thomas’ NHS Foundation Trust, London, UK

P62 Intra-arterial 123I-MIBG injection: a unique case?
C. Leung, J. Siddiqui, E. Nowosinska and H. Jan
Bart’s Health NHS Trust, London, UK

P63 18F-choline PET/MRI in prostate cancer: our initial experience
J. Stirling, J. John, V. Goh and G.J. Cook
Kings College London, London, UK

P64 Optimisation of hybrid simultaneous PET/MRI: our initial experience
Kings College London, London, UK

P65 Organ specific SPECT activity quantification from fused deposition modelled 3D MIRD inserts
A. Robinsona, J. Tippings, D. Cullen, D. Hamilton, C. Oldfield and E. Page
aUniversity of Manchester, Manchester and bThe Christie NHS Foundation Trust, Manchester, UK

P66 Cumulative activity estimation at the voxel level: voxel time activity curve generation effects on the resulting 3D dose distribution
E. Pagea, J. Tippings and D. Hamilton
aThe Christie NHS Foundation Trust and bThe University of Manchester, Manchester, UK
P67 The value of scatter correction in the repeatability of SIRT lung shunting analysis
E. Varzakis, L. Tossici-Bolt, F. Wall, F. Sundram and M. Guy
University Hospital Southampton NHS Trust, Southampton, Hampshire, UK

P68 An inexpensive, simple and low-dose method for administering $^{177}$Lu-DOTATATE
D. Gillett and S. Heard
Addenbrookes Hospital, Cambridge, UK

P69 Radium-223: introducing a new radionuclide
D. Gillett and S. Heard
Addenbrookes Hospital, Cambridge, UK

P70 Impact of production disruption on a newly established bone pain palliation service
S.L. Johns, S. Greenslade, J. Harris, J. Thom and F. Sundram
University Hospital Southampton NHS Foundation Trust, Southampton, UK

P71 Assessment of prognostic factors affecting the radioactive iodine (RAI) outcome in hyperthyroid patients
E. Panagiotidis, P. Chuah, R. Brown, N. Seshadri and S. Vinjamuri
Nuclear Medicine, Royal Liverpool University Hospital, Liverpool, UK

P72 Delivering a xefigo service to NHS patients: lessons learned after one year at the royal surrey county hospital
Royal Surrey County Hospital, Guildford, Surrey, UK

P73 Radioactive iodine therapy following weight loss surgery: practical considerations
N. Mulholland, L. Devlin, D. Ruiz, E. Kalogianni, B. Corcoran, G. Clarke, A. Eccles and G. Vivian
King’s College Hospital NHS Foundation Trust, London, UK

P74 Our experience with the use of $^{89}$Y-SPECT/CT and $^{90}$Y-PET/CT in the assessment of $^{90}$Y microsphere biodistribution after transarterial radioembolisation therapy
P.S. Chuah, R. Brown, I. Hufton, G.O. Jones and S. Vinjamuri
Nuclear Medicine Department, Royal Liverpool University Hospital, Liverpool, UK

P75 The king’s method for infusion pump administration of lutathera@ peptide receptor radionuclide therapy
B. Corcoran, E. Kalogianni, D. Ruiz, N. Mulholland, A. Eccles and G. Vivian
King’s College Hospital NHS Foundation Trust, London, UK

P76 Haematotoxicity of $^{177}$Lu dota-octreotate therapy at 6 months and 2.5 years and overall survival
King’s College Hospital NHS Trust, London, UK

P77 Reassessment of radiation restrictions following xefigo ($^{223}$Ra dichloride) therapy
M.J. Guy*, B. Johnson*, S. Johnsb and F.X. Sundramb
*Medical Physics, University Hospital Southampton and bNuclear Medicine, University Hospital Southampton, Southampton, UK

P78 Five years of molecular radiotherapy (MRT) growth in the UK: survey results from 2007 to 2012
B. Rojas*, C. Hooker*, D.R. McGowan* and M.J. Guy*
*Royal Brompton Hospital, London, Internal Dosimetry Users Group, UK, Kent and Canterbury Hospital, Kent, Oxford University Hospitals NHS Trust, Oxford and University Hospital Southampton, Southampton, UK

P79 Handling radium-223 - which syringe shield should i use?
S. Atkinson and I. Driver
Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne, UK

P80 Revisiting the therapeutic potential of gallium-67
M. Othman*, S. Terry* and P. Blower*
*King’s College London, London, UK and *UITM, Selangor, Malaysia

P81 Radionuclide neuroendocrine therapy in a district hospital setting
C. Lory, P. Ryan and C. Bowen
Medway Maritime Hospital, Gillingham, UK

P82 Which pharmacological stress agent to use in a patient with porphyria? A case report with literature review
A.V. Grundy, A. Hosur, A. Clarke, H.M. Cripps and S. Dizdarevic
Brighton and Sussex University Hospitals NHS Trust, Brighton, UK

P83 Experience with qualification of a Laura radiochromatogram scanner
R. Harrison, M. Grenan and J. Croasdale
Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK
P84 Optimising patient pathway for radium-223 therapy of bony metastases
S. Atkinson, I. Driver, J. Frew, R. McMenemy, A. Azzabi and I. Pedley
Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK

P85 Radionuclide imaging of hematogenously distributed Staphylococcus Aureus infectious foci and biodistribution of tracers in domestic pigs
aUniversity Hospital of Copenhagen, North Zealand Hospital, Department of Diagnostic Imaging, Copenhagen, Denmark, bUniversity of Copenhagen, Veterinary Disease Biology, Copenhagen, Denmark, cUniversity Hospital of Aarhus, Department of Nuclear Medicine and PET Centre, Aarhus, Denmark, dUniversity Hospital of Aalborg, Department of Clinical Microbiology, Aalborg, Denmark, eUniversity Hospital of Aalborg, Department of Clinical Medicine, Aalborg, Denmark and fUniversity Hospital of Aalborg, Department of Nuclear Medicine, Aalborg, Denmark.

P86 The search for an optimal approach to post-surgical 131I thyroid remnant ablation
V.R. McCready, G. Flux, A. Hosur, A. Nahum and S. Dizdarerc
Royal Sussex County Hospital, Brighton E Sussex, UK, Institute of Cancer Research, Sutton Surrey, UK and rThe Clatterbridge Cancer Centre, Bebington, Wirral, UK

P87 Labelling efficiency of cheese as an alternative meal for solid gastric emptying scintigraphy
S. Randerson, S. Renn and G. Wright Hull and East Yorkshire Hospitals NHS Trust, Cottingham, UK

P88 Practical, technical and radiation protection factors influencing a PRRT NET therapy service: the expanded role of the technologist
R. Leshen, I. Mateo-Vito and S. Navalkissoor Royal Free London NHS Foundation Trust, London, UK

P89 Renal parenchymal analysis: 99mTc-MAG3 versus 99mTc-DMSA
T. De Sousa and D. Bailey Guy’s and St Thomas’ NHS Foundation Trust, London, UK

P90 Radiation protection advice for nurses looking after radionuclide therapy patients
S.L. Johns, R. Pinchone, C. Joy, B. Johnson and D. Saggs University Hospital Southampton NHS Foundation Trust, Southampton, UK

P91 Pitfalls and technical artefacts in infrequently performed physiological nuclear medicine tests
E. Sunga, I. Mateo-Vito and S. Navalkissoor Royal Free London NHS Foundation Trust, London, UK

P92 Octreotide or dotatate: is there any difference?
S. Johnson and D. Bailey Guy’s and St Thomas Hospital, London, UK

P93 Pearls and pitfalls in hepatobiliary scintigraphy protocols in a large teaching hospital - a trainee technologist’s perspective
N. Pereira, A. Cheetham, N. Gulliver, A. Eccles, N. Mulholland and G. Vivian King’s College Hospital NHS Foundation Trust, London, UK

P94 Adjusting to change: our experience of changing from 99mTc-DTPA to 51Cr-EDTA for GFR studies
J. Wilkins, G. Lewis, M.J. Guy and S. Johns University Hospital Southampton NHS Foundation Trust, Southampton, UK

P95 Experiences of an on-site cyclotron in neurological imaging
A.R. Cabrall, J. O’Doherty, J. John, A. Jacob, C. Abreu, S. Pereira and L. Alves PET Imaging Centre, Division of Imaging Sciences and Biomedical Engineering, King’s College London, King’s Health Partners, St Thomas’ Hospital, London, UK

P96 Sentinel node injections: an audit of injected activities
A. Boyce Portsmouth Hospitals NHS Trust, Portsmouth, UK

P97 Establishing local dose reference levels within paediatric SPECT-CT: a single centre experience
B. Thurlow, E. O’Mahoney, L. Biasoni and C. Young Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK

P98 Monte carlo modelling 90Y SPECT for molecular radiotherapy
C. Oldfield, D. Cullena, A. Robinsona, J. Tippingb, D. Hamiltonb and E. Pageb aUniversity of Manchester and bThe Christie NHS Foundation Trust, Manchester, UK

P99 Erroneous scatter correction on FDG PET study of patient with activity in nephrostomy drainage bag
I.S. Armstrong, K.J. Saint and J.M. James Central Manchester University Hospital, Manchester, UK
P100 Cyclotron production of the positron emitting radiometal yttrium 86
C. Marshalla, A. Dabkowskia and M. Talboysa,b
aCardiff University, Cardiff and bCardiff and Vale UHB, Cardiff, UK

P101 Commissioning of a new SeHCAT detector and comparison with an uncollimated gamma camera
J. Himsworth, J. Taylor and P. Hillel
Sheffield Teaching Hospitals NHSFT, Sheffield, South Yorkshire, UK

P102 Blood dosimetry for radioiodine thyroid ablation
K. Thomson and A. Hallam
Oxford University Hospitals NHS Trust, Oxford, UK

P103 Comparison of the quantification of ¹⁸F for a radionuclide calibrator, pre-clinical PET-CT scanner and gamma counter
J.M. Pricea,b, I. Murraya and M.O. Leachc,d
aInstitute of Cancer Research, London, UK, bCHR-UK Cancer Imaging Centre, London, UK and cRoyal Marsden Hospital NHS Trust, London, UK

P104 Evaluation of the performance of a pre-clinical PET-CT scanner using ⁶⁷Cu, with comparison to ¹⁸F
J.M. Pricea,b, I. Murraya and M.O. Leachc,d
aInstitute of Cancer Research, bCHR-UK Cancer Imaging Centre and cRoyal Marsden Hospital NHS Trust, London, UK

P105 Assessing the effects of planar astonish processing on clinical bone and thyroid images
N. Davis
Mount Vernon Hospital, Northwood, Middlesex, UK

P106 The impact of background ratios in calibration phantoms on the accuracy of dosimetry for ⁹⁰Y DOTATATE therapy
T. Sandersona,b, J. Geara, I. Murraya and G. Fluxa
aSt George’s Healthcare NHS Trust and bThe Royal Marsden NHS Foundation Trust, London, UK

P107 Low and medium-energy general purpose collimators provide improved detectability over lowenergy high spatial resolution collimators for imaging neuroendocrine tumours with ¹²³I mIBG
R. Gregorya, I. Murraya, J. Geara, M. Aldridgea, L. Fowkesa, W. Waddingtona, S. Chuaa and G. Fluxa
aRoyal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, UK and bUCL Institute of Nuclear Medicine and UCL Hospitals NHS Foundation Trust, London, UK

P108 Automatic calibrator linearity freeware receptor radionuclide therapy
D. Rushfortha, J. Keightleya, B. Pratta and G. Fluxa
aThe Royal Marsden NHS Foundation Trust, London, UK and bThe National Physical Laboratory, Teddington, UK

P109 How do you measure intrinsic uniformity on a siemens symbia gamma camera?
I.S. Armstrong and K.J. Saint
Central Manchester University Hospital, Manchester, UK

P110 Characterisation of the lynax auto dispensing for ¹⁸F FDG on a mobile PET/CT scanner
A.G. Irwin, A. Paramithas, A. Daley and D. Wark
aSt. George’s Hospital, London and bAlliance Medical Ltd, Warwick, UK

P111 Physicists in the world of radiopharmacy - a novel approach to RCP QC
J. Speakmana, D. Ibbett and J. Walker
aRoyal Derby Hospital, Derby and bUniversity of Sheffield, Sheffield, UK

P112 Urinary excretion of ¹²³I serum amyloid P component (SAP)
J. Pagea and J. Jones
aNational Amyloidosis Centre and bRoyal Free London NHS Foundation Trust, London, UK

P113 Thyroid ablation restriction times – patient specific modelling of retained activity and dose rates
J. Himsworth, M. Singleton and P. Harris
Sheffield Teaching Hospitals NHSFT, Sheffield, South Yorkshire, UK

P114 An investigation into unusual leak test results
J. Solomon, A. Moreton and C. Nottage
Colchester Hospital University Foundation Trust, Colchester, Essex, UK
Alliance Medical operates a national network of over 50 MRI, CT and PET-CT static imaging centres. In addition, we provide mobile medical imaging services to over 100 NHS and independent sector hospitals through our fleet of mobile scanners.

In early 2015, along with partners in a collaborative network, we were successful in our bid to provide PET-CT imaging services on behalf of the NHS. As a result, we will be significantly increasing PET-CT scanning capability with an investment of over £85m across 30 sites in England working in partnership with the NHS and independent sector.

Alliance Medical also operates an integrated national network of four radioactive isotope production facilities and an integrated SPECT radiopharmaceutical distribution agreement (including Mo-99 generators) as part of a goal to provide a secure of supply of radionuclides / radiopharmaceuticals to UK patients and the UK diagnostic imaging market.

For further information, please visit our stand or contact us: Tel: 01926 482222 web: www.alliancemedical.co.uk or email: info@alliance.co.uk

Ashby Gorman Baker Stand 12

Ashby GB is once again very pleased to support BNMS at this year’s conference in Brighton.

An independent company which continues high quality maintenance and repair of many different Gamma Camera Systems throughout the UK and several European Countries.

Our commitment is totally customer focused, providing an excellent and professional service which is of the highest quality and cost-effective of which we are very proud.

We look forward to welcoming you to our stand

Bartec Technologies Limited Stand 4

Bartec supply, deliver, install and maintain a range of Clinical and Pre-Clinical Molecular Imaging Systems and associated Accessories, Digital X-ray Systems, Radiology C-Arm and Ultrasound Tables, Radiation Monitoring, Protection and Decontamination Products.

Bayer UK Stand 9

Bayer Healthcare Pharmaceuticals aims to launch and develop products that improve people’s quality of life. To achieve this, Bayer Healthcare Pharmaceuticals concentrates on the research and development of innovative drugs and novel therapeutic approaches in the major therapeutic groups of cardiology, oncology, ophthalmology, haematology and gynaecological therapy.

Within oncology, the franchise includes three marketing products (Xofigo®, Nexavar® and Stivarga®) and several compounds in various stages of clinical development. These products reflect the company’s approach to research, which prioritises targets and pathways with the potential to impact cancer treatment. Our pipeline explores specific treatment approaches for various tumors, including such common types of cancer as prostate, lung and breast cancer, as well as rarer forms like kidney, liver and thyroid cancer.

Bright Technologies Ltd Stand 19

Bright Technologies Ltd, often known as Bri Tec, has a renowned reputation for its expertise in Radiation Protection, Radio-Radiopharmaceutical Q.C., and MRI Accessories. A key feature of Bri Tec is our Sheffield based in-house design and manufacturing facility. We have wide ranging experience of working with many NHS Trusts, Further Education Institutes and commercial companies. Our in-house design team and production facility allows us to take your ideas and designs, develop them and, put them into production. This versatility allows Bri Tec to undertake both low and high volume production runs.

In addition we are able to bespoke manufacture room installations so that the room space is optimally utilised in terms of both space and user friendliness. What do we mean by this? The installation fits both the user’s requirements and the room - not the other way round! For further information on our products and facilities please do not hesitate to contact us.

BTG Stand 15

At BTG we are focused on bringing to market innovative products in specialist areas of medicine to better serve doctors and patients. Our growing portfolio of Interventional Medicine products is designed to advance the treatment of liver tumours, severe blood clots, varicose veins and advanced emphysema, while our Specialty Pharmaceuticals portfolio offers antidotes that alleviate toxicity and treat rare conditions.

To charge up your devices, gain internet access and pick up additional copies of our official journal NMC; please visit us at the BNMS booth.

Delegates will also find information on membership, future meetings of the BNMS, brochures and other journals.
Cirrus Containments Ltd

Cirrus Containments is the UK manufacturer of a unique range of containment and aseptic isolators. Our experience within the nuclear, pharmaceutical and healthcare industries has enabled us to develop and manufacture isolator units which combine leading edge technology with a modern design. Our isolator units are all based upon a standard modular method of construction, enabling us to standardise parts, hardware and control system software across the complete range.

Company Website www.cirruscontainments.com

Diagnostic Imaging Ltd

We specialise in only Nuclear Medicine products. Established in 2000 we have a wealth of experience in Nuclear Medicine procedures. We supply SmartVent (the UK’s bestselling radioaerosol delivery system), DDD renal single head and mobile single head) raytest quality synthesisers) and a wide range of radiopharmaceuticals and radioisotopes (Polatom, Jubilant Draximage, ITG, Medi-Radiopharma and Iso-Tex) for diagnostic and therapy work.

Eli Lilly

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers — through medicines and information — for some of the world’s most urgent medical needs. Lilly has a long heritage in the UK, opening its first facility outside North America in London in 1934. Today Lilly has around 2500 staff in the UK, working across three sites: a sales and marketing operation in Basingstoke, a R&D base in Surrey and a bio-tech manufacturing facility in Liverpool. www.lilly.co.uk

GE Healthcare

GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients.

Hermes Medical Solutions Ltd

HERMES Medical Solutions, established in 1976 by Jan Berling, Founder and President, has been first-to-market with over 88 medical software applications, including the first SPECT reconstruction software in 1977 and, in 2014, the latest milestone: HERMES SUV SPECT®

With HERMES it is now also possible to obtain Standardized Uptake Value (SUV) for SPECT studies. HERMES launched its unique HERMES SUV SPECT® software package at the 2014 EANM in Gothenburg, Sweden.

- Works with your existing and new SPECT/CT systems
- Available on HERMES Cloud and HERMES Workstations / Servers.
- State-of-art SPECT reconstruction algorithm with attenuation correction, Monte-Carlo-based scatter correction and resolution recovery Available for all routine clinically-used radionuclides and collimators.
- Faster easier and more reliable visual image comparison
- Enables quantitative comparison of SPECT scans without need for additional normalisation
- Improved image quality
- Reduce radiation dose or acquisition time

Please join us on Booth 23 to find out more about this revolution in Nuclear Medicine imaging!

Imaging Equipment Limited

Imaging Equipment Limited (IEL) is the largest independent distributor of specialist Nuclear Medicine products in the UK and Ireland and offers a wide portfolio of products including Radiopharmaceuticals, PET injectors, Radionuclide Therapies, shielding and radiation protection.

IEL are extremely proud to be representing such global market leaders in the Nuclear Medicine arena as; Advanced Accelerator Applications (AAA)*, Cyclomedica, Eckert & Ziegler, ROTOP and Tema, thus being able to accurately match customers’ requirements and build packages that meet both their technical specifications and budgetary demands.

IEL’s team of specialist Nuclear Medicine sales consultants, supported by a dedicated and experienced technical team, provide a personal and high-quality customer service across the UK and Ireland.*Imaging Equipment Limited is owned by Advanced Accelerator Applications (AAA) of St Genis Pouilly (France).

Immunomedics

Immunomedics GmbH is a subsidiary of Immunomedics, Inc., a New Jersey based biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases.

The company has developed a number of advanced proprietary technologies to create humanized antibodies that can be used either alone in unlabeled or “naked” form, or conjugated with radioactive isotopes or chemotherapeutics, in each case to create highly targeted agents. The European headquarters is Marketing Authorisation Holder of LeukoScan®, an antibody for Tc labelling, approved for the scintigraphic diagnosis of osteomyelitis including diabetic feet. As an antibody Fragment it does not cause HAMA as known for intact mouse antibodies. LeukoScan is distributed by Immunomeds GmbH into more than 20 countries including UK.

LabLogic Systems Ltd

LabLogic provide a range of market leading products which can be found in some of the world’s most prestigious PET and Nuclear Medicine laboratories. Our products include a range of QC equipment including innovative r-TLC, r-HPLC instruments and a single point of control radiochromatography software package Laura for PET.

Furthermore LabLogic offer PETra, a purpose built PET LIMS system designed to improve efficiency and compliance. PETra directly captures data from all the equipment used. It acts as a central repository all information within PET production including batch record management, QMS, trending, inventory, instrument maintenance etc.

Link Medical Ltd

Link Medical specialise in medical imaging, archiving and connectivity solutions. We provide off-the-shelf and customer specified software solutions across radiology, nuclear medicine and radiotherapy.

We work for hospital departments, the private sector and all the large medical equipment manufactures, within the UK, Europe, North America and Japan.

Southern Scientific

Southern Scientific has been supplying equipment for Nuclear Medicine, X-Ray QA and Radiation Protection applications for over 25 years, including specialist Gamma Camera’s (MIE and Digirad), X-Ray QA products (RTI, Pehamed, RSD, The Phantom Laboratory), Nuclear Medicine based products (Capintec, Amici) and our own range of radiation/contamination monitoring instruments.
With a history of more than 145 years, we are a global leader in medical imaging specialising in radioactive isotopes and pharmaceuticals for nuclear medicine and diagnostics. We are delighted to be supporting the BNMS this year and will be holding regular on-stand education presentations to show you what we are doing to help stabilise the supply of Molybdenum for the future. Check the screen on our stand for presentation times.

Mediam Pharma is a pharmaceutical company created in November 2000, based in France and United Kingdom, and specialised on the commercialisation of radiopharmaceutical products used in the field of nuclear medicine as tracers in medical imaging for diagnostic use. The company is marketing all these products in Europe (United Kingdom, Ireland, France, Netherlands, Sweden, Finland, Portugal, Spain, Greece, etc.), in Asia and in the Middle East.

We specialise in only Nuclear Medicine products. Established in 2000 we have a wealth of experience in Nuclear Medicine procedures. We supply SmartVent the UK’s bestselling radioaerosol delivery system, DDD gamma cameras (dual head variable angle and whole body, cardiac, renal single head and mobile single head) raytest quality radiopharmaceutical laboratory equipment (radio-TLC, HPLC and Ga synthesizers) and a wide range of radiopharmaceuticals and radioisotopes (Polatom, Jubilant DraxImage, ITG, Medi-Radiopharma and Iso-Tex) for diagnostic and therapy work.

MiLabs provides high-end and hybrid molecular imaging systems (PET,SPECT, CT) for biomedical research. Today these MiLabs systems, with proven quarter-mm SPECT and three-quarter mm PET resolution, contribute worldwide to the development of new diagnostic solutions and therapies for diseases such as diabetes, cancer, cardiac and neurodegenerative diseases. MiLabs U-SPECT4CT provides researchers by far the fastest, most sensitive and highest resolution small-animal SPECT imaging currently available and comes with low dose ultra-high resolution integrated CT. The VECTor option for this system enables simultaneous and ultra-high resolution PET and SPECT. MiLabs systems have in common that they are extremely reliable, versatile, and user friendly.

Packexe® Ltd is a UK-based company specialising in protection films for the trade, safety, health and consumer markets. Established in 1989, the company’s diverse portfolio includes Packexe® Smash, Sharpswrap, flooring and multi-surface protection films, Handy Wrap and Physio Wrap. The company is known for its commitment to quality and constant innovation producing reliable, affordable and indispensable products. Packexe® is the world’s leading supplier of innovative protection films. The highly awarded product range is seen as the best available in sectors ranging from Fire and Rescue and Nuclear Medicine to Warehousing and Construction.

At Philips we are dedicated to creating the future of healthcare and saving lives. Our understanding and delivery of clinical solutions across the entire healthcare continuum, from healthy living and prevention to recovery and long-term management at home means we can create more effective, integrated care solutions. Come and ask us about the first installation of the world’s first Digital PET/CT Scanner, Philips Vereos. The Vereos provides improved contrast and superb SUV quantitation while delivering fast scans and fast post-processing to speed up your workflow.

Qados supplies a wide range of radiology, dosimetry, QA and other associated products to the medical, hospital and research sectors. Qados is focused on providing premium products in the areas of radiotherapy, nuclear medicine, x-ray, Oncology, health physics and radiation monitoring. Qados is the exclusive UK distributor for many of the key manufacturers in these sectors. We also provide services to many major UK and Irish hospitals and institutions for the installation and on-going maintenance of installed systems Including; calibrations for test equipment and radiation monitors. Comprehensive support contracts for equipment are also offered via our field based service engineers.

Siemens Healthcare is one of the world’s largest suppliers to the healthcare industry and a trendsetter in medical imaging, laboratory diagnostics, medical information technology and hearing aids. Siemens offers its customers products and solutions for the entire range of patient care from a single source - from prevention and early detection to diagnosis, and on to treatment and aftercare. By optimising clinical workflows for the most common diseases, Siemens also makes healthcare faster, better and more cost-effective.

Sirtex Medical Europe GmbH is a wholly-owned subsidiary of Sirtex Medical Limited, a publicly-listed company on the Australian Securities Exchange engaged in the field of liver-directed therapies for oncology. Our innovative technology, SIR-Spheres® microspheres, was approved in 2002 for use in the treatment of un-resectable liver tumours within the European Union under a CE Mark and for the treatment of colorectal cancer liver metastases in combination with FUDR intra-arterial chemotherapy by the US Food & Drug Administration. SIR-Spheres microspheres are presently used to treat a variety of un-resectable liver metastases as well as in hepatocellular carcinoma at over 100 institutions throughout Europe.

For more information, please contact Head Office: Sirtex Medical Europe GmbH Joseph-Schumpeter-Allee 33 53227 Bonn, Germany Tel: 00 49 228 1840730 www.sirtex.com

The British Institute of Radiology is the oldest radiological society in the world which welcomes everyone working in the field of radiology, radiation oncology and the underlying sciences. Whether you are a radiologist, radiographer, medical physicist, radiotherapist, oncologist or anyone with a professional interest in the field, there is a membership category to suit your needs.

The College of Radiographers is committed to developing and promoting a wider understanding of the science of clinical imaging and radiation therapy. We promote the accreditation of professional standards across the imaging and radiotherapy workforce and aim to build professional credibility through research. We want to be informed by our patients and also help our patients and public to better understand the role of imaging and radiotherapy in their healthcare. We seek to collaborate and partner on a global basis to ensure that the very best standards of practice are shared for the benefit of all.

A major feature of our educational work recently has been the development of e-LfH learning units for nuclear medicine practitioners – come and see these excellent resources on our stand.

We welcome visitors to our stand where representatives will be on hand to discuss a wide range of topics, including regulation, workforce shortages and development, hybrid imaging skills, continuing professional development, etc. So, please visit us – members and non-members are all very welcome.
YOU'LL BE SURPRISED
HOW MUCH YOU CAN
GET OUT OF OUR
MEMBERSHIP

JOIN THE SOCIETY TODAY AND
HELP US SHAPE THE FUTURE OF
NUCLEAR MEDICINE
ENQUIRE AT THE MAIN DESK FOR FURTHER DETAILS